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ABSTRACT
ENGINEERING SURFACE FUNCTIONALITY OF GOLD NANOPARTICLES FOR
THERAPEUTIC APPLICATIONS
FEBRUARY 2012
CHAE KYU, B.A., INHA UNIVERSITY
M.A., INHA UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Vincent M. Rotello
Over the past few decades, tremendous efforts have been made to develop
nanomaterials for biotechnological applications such as therapeutics. Understanding
and engineering interfaces between biomacromolecules and nanomaterials is a key to
the creation of successful therapeutic systems. My research has been oriented toward
developing therapeutic systems using gold nanoparticles (AuNPs) incorporating
material science, organic synthesis, and biology. For this purpose, mixed monolayerprotected AuNPs (~2 nm core size) with various functional groups have been employed
for triggering therapeutic effects. Several strategies have been accomplished using
anticancer drugs that non-covalently and covalently incorporate onto AuNPs as a drug
delivery carrier. Alternatively, AuNPs were developed by regulating host-guest
complexation processes inside the cell, allowing control of the therapeutic effect of the
AuNP. In addition, by using host-guest chemical events on the AuNPs, exocytosis of
the AuNPs was controlled, enabling their prolonged retention inside of the cells,
providing new strategies for improving conventional drug delivery systems. Therefore,
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engineering of the AuNP surface can afford new pathways for designing and improving
therapeutics.
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CHAPTER 1

GOLD NANOPARTICLES IN THERAPEUTICS

1.1 Introduction
Nanoparticles provide a useful platform, demonstrating unique properties
gleaning a wide range of therapeutic applications.
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Monolayer protected metal

nanoparticles particularly have proven to be the most versatile and widely used
constituents in biotechnology.2, 3, 4, 5 Nanoparticles represent hybrid systems of nano-scale
metal cores covered by a self-assembled monolayers of organic ligands. The use of
nanoparticles in therapeutic applications takes advantage of both the dimensions and the
physical properties of the inorganic core, as well as the functions of the organic surface
periphery.
Nanoparticles exhibit a number of unique physical and chemical properties
relative to bulk material. The novel properties of nanoparticles arise from a variety of
attributes, including their enormous surface area. In addition, the versatile and tunable
properties of nanoparticles are based on their component, size, shape, functionalized
surface, and chemical surroundings. The unique properties of nanoparticles have attracted
great interest in the scientific community and have been utilized in various chemical and
biological applications, including electronic and optical studies, chemical and biological
sensing, cell labeling and imaging, and cancer therapy.6, 7, 8, 9, 10 Table 1.1 list some well
known core materials with their corresponding surface ligands and their various
biological applications.
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Table 1.1 Characteristics, ligands, and representative applications for various metal and
semiconductor materials.
Core
Characteristics
material

Ligand(s)

Applications

Thiol, disulfide,
phosphine, amine

Biomolecular
recognition, delivery,
sensing, therapeutics

Au

Optical
absorption,
fluorescence and
fluorescence
quenching,
stability

Ag

Surface-enhanced Thiol
fluorescence

Pt

Catalytic property Thiol, phosphine, Bio-catalyst, sensing
amine, isocyanide

CdSe

Luminescence,
photo-stability

Thiol, phosphine,
pyridine

Imaging, sensing

Fe2O3

Magnetic property Diol, dopamine
derivative, amine

MR imaging and
biomolecule
purification

SiO2

biocompatibility

Biocompatible by
surface coating

Sensing

Alkoxysilane

Of these metal nanoparticles, the utility of gold nanoparticles (AuNPs) in biology
has attracted attention due to its biocompatibility,11 controlled fabrication, and functional
versatility. 12 , 13 , 14 Stimulated by the pioneering work of Brust et al. in 1994, 15 thiolprotected AuNPs have evolved to one of the most widely studied particle-ligand systems.16
The optical, electronic and bioinert properties of the gold core combined with the versatile
surface functionalization facilitate the applications of these materials in both fundamental
research and industrial development. 17, 18, 19, 20 These functional nanomaterials have shown
promising potential in electronics,21 catalysis,22 biosensing,23 and nanomedicine.24
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Figure 1.1 Schematic illustration of monolayer-protected gold nanoparticles: the
inorganic gold core protected by an organic monolayer that can feature chemically
different end group for a myriad of biomedical applications.
The functionalization of gold clusters is achieved through Brust-Schriffrin
reduction followed by Murray place-exchange reaction 25 with appropriate functional
ligands. The incorporation of multiple functionality within the scaffold of a single cluster
coupled with a scale comparable with biomacromolecules (e.g. proteins and DNA)
provides multiple applications at the interface of biotechnology and nanomaterials. For
instance, some recent studies have shown that proper surface functionalization holds great
promise in disrupting protein-protein interaction, 26 regulating DNA transcription, 27 gene
transfection,28 etc. This thesis work utilized AuNP as a scaffold for designing systems for
therapeutic applications. Therefore, as a background to this work, synthesis and
functionalization, properties, and some therapeutic applications of AuNPs will be discussed
in this chapter.
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1.2 Synthesis and surface functionalization of gold nanoparticles
AuNPs can be synthesized either through chemical reduction of gold salts or
through the physical treatment of bulk gold. The synthesis of AuNPs has been widely
explored during the past few decades. Concurrently various strategies have been applied
to control their size, shape, stability, solubility, and surface functionality. AuNPs of
various sizes can be prepared by using appropriate stabilizing agents during the chemical
reduction of gold salts. These stabilizing agents provide the necessary barrier to avoid
particle coalescence. Some common synthetic methods of AuNPs are summarized in
Table 1.2.
Table 1.2 Synthetic methods for AuNPs of diverse core size.
Core size (d) Synthetic methods
1-2 nm
Reduction of AuCl(PPh3) with diborane or sodium
borohydride
1.5-5 nm
Biphasic reduction of HAuCl4 by sodium
borohydride in the presence of thiol capping agents
5-8 nm
Reduction of HAuCl4 by sodium borohydride in
the presence of TOAB
8-20 nm
Reduction of HAuCl4 by oleyl amine in water
under heating
10-40 nm
Reduction of HAuCl4 with sodium citrate in water

Capping agents
Phosphine

References
29,30,31

Alkanethiol

32,33,34

Quaternary ammonium salt 35
(TOAB)
Oleyl amine
36, 37
citrate

38,39,40

In 1994, the breakthrough in AuNP synthesis was achieved by Brust and
Schriffin.15 AuNPs soluble in organic solvents were synthesized by using the surfactant
tetraoctylammonium bromide (TOAB) to transfer hydrogen tetrachloroaurate from
aqueous phase to toluene phase. In this method, Sodium borohydride was used as
reducing agent in the presence of alkanethiols. This methodology produces relatively
monodisperse AuNPs protected by thiol ligands and with diameters ranging from 1.5 to 5
nm. The nanoparticle size is controllable by varying the reaction conditions such as gold-
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to-thiol ratio, reduction rate, and reaction temperature. Thiol-protected AuNPs possess
higher stability compared to most other AuNPs due to the synergic effect of strong thiolgold interactions and van der Waals attractions between the ligands. These nanoparticles
can be thoroughly dried and redispersed in solution without any aggregation. In the
biphasic reduction protocol, slightly larger nanoparticles can be achieved by using
quaternary ammonium instead of a thiol ligand and show considerable stability in
solution. These particles serve as excellent precursors for further functionalization of
nanoparticles.
Various capping agents (e.g. amino acid,41 oelyl amine, and aliphatic and aromatic
amines42, 43) have been introduced to reduce gold salts into nanoparticles with different
core sizes. The size and shape of AuNPs can be further manipulated by physicochemical
treatments such as light-irradiation and thermolysis. For example, conventional
ripening44, 45, 46 and digestive ripening47, 48 treatments have been conducted to control the
nanoparticle size. UV and laser irradiation provides another powerful approach to
improve quality of the nanoparticle.49, 50
The capping agents used for synthesizing AuNPs are generally lacking in
chemical functionality, thus restricting their applications in therapeutics. Place-exchange
process introduced by Murray is an efficient approach for functionalizing surface of
AuNPs (Figure 1.2).25 During a place-exchange reaction, the thiol ligands initially
anchored on the nanoparticle surface are replaced by the external thiol ligands in an
equilibrium process.51 The loading of functional ligands can be controlled by modulating
the reaction time and/or the amount of incoming ligand. Mixed monolayer-protected gold
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clusters can also be obtained by using a mixture of two or more ligands as the incoming
thiol agents.

Figure 1.2 Synthesis of AuNP and its surface functionalization through place exchange
reaction.
Labile

capping

agents,

such

as

citrate,

52

triphenylphosphine,

53

and

dimethylaminopyridine,54 can be displaced by thiols under mild reaction conditions with
no residual capping agent. Citrate-stabilized AuNPs are important precursors for large
functionalized colloidal ensembles such as those carrying oligonucleotide, protein, or
antibody functionalities. 55, 56 However, chemisorption of thiol ligands onto the citratestabilized nanoparticles leads to their irreversible aggregation. 57 Therefore, to prevent
aggregation, nonionic surfactant such as Tween 20 is usually used during the placeexchange. The thiol ligands on gold surface possess a certain level of mobility and
consequently they can undergo repositioning on the surface to optimize interaction with
analytes.58

1.3 Cellular interaction of gold nanoparticles
For developing a therapeutic system with AuNPs, an understanding of the
interaction of AuNPs with cells is important. Cellular uptake and intracellular fate of
AuNPs depend on surface functionality and size.59 Charge is an important determinant,60
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Rotello and Vachet have demonstrated that cellular uptake of functionalized AuNPs is
dependent on both charge and hydrophobicity.61 Stellacci et al. have reported that cell
membrane penetration of nanoparticle is also dependent on ligand shell morphology,62
with “striped” (structured ligand shell) nanoparticles apparently capable of directly
passing through the plasma membrane of the cells without creating pores on cell
membrane that can cause cytotoxicity (Figure 1.3).

Figure 1.3 Schematic diagrams of the ligand shell structure of the nanoparticles and
representative STM images (scale bars 5 nm).

Furthermore, organelle-specific localization of particles can be easily achieved by
decorating the surface with a targeting moiety. For example, Feldheim et al. have
demonstrated nuclear targeting of particles modified with nuclear localization sequence
(NLS).63 Recently, Brust et al. have used transmission electron microscopy64 to show that
specific cellular targets such as the nucleus and other organelles can be targeted by
modifying the particle surface with cell penetrating peptides (CPPs) (e.g. the
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oligopeptides TAT (AGRKKRRQRRR) and Pntn (GRQIKIWFQNRRMKWKK)) and
the nuclear localization sequence (NLS: GGFSTSLRARKA) (Figure 1.4).

Figure 1.4 Nuclear targeting (A) by PEG-modified nanoparticles functionalized with a
combination of CPPs (2% TAT and 2% Pntn) and 2% NLS. Nanoparticles are
highlighted by red circles. The nuclear envelope with nuclear pores (arrows) is clearly
shown in this image. The nucleus is denoted n, and the cytosol c. Unusual perinuclear
membranous structures (B and C) that are highly loaded with nanoparticles are typically
also observed under these conditions. Nuclear targeting is enhanced in comparison with
experiments in the absence of CPPs (D). Scale bars are 200 nm.

Particle size provides the second key determinant of particle uptake. Chan et al.
have demonstrated that cellular uptake depends on the size of nanoparticles.65 AuNPs (2100 nm) coated with Herceptin were fabricated and tested for ErbB2 receptor-mediated
internalization in breast cells. They found that most efficient cellular uptake occurred
with the 20~50 nm particles and programmed cell death (apoptosis) was enhanced by
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particles the 40–50 nm range. The authors also have investigated the effect of AuNP size
(10-100 nm) on passive targeting of tumors in vivo.66 The larger nanoparticles remained
near the vasculature, whereas smaller nanoparticles rapidly diffused from blood vessels to
tumor matrix (Figure 1.5).

Figure 1.5 Particle size-dependent permeation of the tumor interstitial space. (A-C)
Histological samples were obtained for 20, 60, and 100 nm particle sizes at 8 h
postinjection (HPI). (D) ImageJ software was used to generate contrast-enhanced images
for densitometry analysis. (E) Densitometry signal was quantified at 10m distances
away from blood vessel centers 8 HPI and was normalized to the signal at 0-10 μm66.

1.4 Gold nanoparticles in drug delivery
Considerable effort has been focused on the creation of drug delivery systems
(DDS) for improving efficacy of cancer chemotherapy, with the goals of enhancing
therapeutic selectivity and efficacy. 67 One area where DDSs have proved highly
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beneficial is in targeted delivery, where marked improvements in chemotherapy have
been achieved through passive and/or active targeting approaches with nanocarriers
including liposomes, 68 polymer micelles and vesicles, 69 dendrimers, 70 and metal
nanoparticles.71
AuNPs have recently emerged as highly promising DDSs.72 AuNPs have multiple
aspects that make them well-suited for use in delivery applications over other
nanocarriers. First, AuNPs of many different sizes (1-150 nm) can be fabricated in a
controlled fashion with control over size dispersity,73 while polymer based carriers have
the issue caused by the intrinsic heterogeneous structure of polymers due to a high
polydispersity index indices. Furthermore, due to their high surface area to volume ratio,
a high density of ligands can be archived on the surface of AuNPs for targeting or drug
loading purpose. For example, 2-nm core sized AuNP has around 100 lignads on
particles.34 Second, functional diversity can be readily achieved by creation of
multifunctional monolayers using techniques such as the ligand place-exchange reaction,
allowing multiple functional moieties such as anticancer drugs and targeting agents to be
placed onto the particle surface. In terms of the mitifunctionalization, dendrimers are a
promising nanocarrier with a well defined structure. However, many repetitive steps for
synthesis and expensive production are major challenges. Lastly, the gold core is
essentially inert, non-toxic, and biocompatible.74
The facile functionalization of AuNP surface has enabled their use in a variety of
delivery strategies. In one approach, prodrugs can be covalently conjugated to AuNPs via
cleavable linkers. Alternatively, hydrophobic drugs can be non-covalently loaded onto
AuNPs, allowing conjugation without structural modification of the drug payload. Once
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loaded, AuNP payloads can be released by either internal (e.g. glutathione)12 or external
(e.g. light) 75 stimuli. The versatility of the AuNP monolayer is central to release
mechanisms, providing tunability for endogenous release mechanisms and a functional
platform for external release strategies.

1.4.1 Drug attachment and release strategies using gold nanoparticles
Both the transport and release of drugs play critical roles in providing effective
delivery systems. In general drugs can be loaded onto nanocarriers by either covalent
conjugation or non-covalent interactions. 76 The non-covalent approach employs active
drugs while the covalent attachment generally requires intercellular processing of a
prodrug.77 The ease of controlling the functionality and structure of AuNP monolayers
makes them excellent platforms for DDS creation.
DDS systems based on glutathione (GSH)-mediated payload release exploit the
dramatically higher intracellular GSH concentration (1–10 mM)78 relative to extracellular
thiol levels (GSH 2 M, cysteine 8 M). 79 The high levels of intracellular GSH can be
used to release prodrugs (payloads) on AuNPs through either place-exchange reactions at
the core or via disulfide exchange. Importantly, the monolayer of nanoparticles can
provide steric shielding against exchange with surface cysteines of proteins in the
bloodstream,80 enabling their potential use in vivo.
In early studies, Rotello et al. developed a nanoparticle-based delivery system
featuring glutathione release. The particles (core diameter: ~ 2 nm) featured a mixed
monolayer composed of cationic ligands (TTMA) and fluorogenic ligands (HSBDP)
(Figure 1.6). The cationic surface of the nanoparticles facilitated the penetration through
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cell membrane, and the payload release was triggered by intracellular glutathione (GSH).
In this delivery system, the BODIPY moiety of the HSDBP ligand was non-fluorescent
when attached to the particle due to fluorescence quenching by the Au core. 81 The
fluorescence was recovered upon GSH treatment in cuvette, or with intracellular thiols in
human liver cells (Hep G2). GSH-controlled release of the dye was verified by treating
mouse embryonic fibroblast cells (MEF, having >50% lower intracellular GSH levels
than HepG2) with varying concentration of glutathione monoester (GSH-OEt),
transiently increasing glutathione level inside the cells. In these studies, a dose-dependent
increase in fluorescence was observed with increasing GSH-OEt concentration. In a
similar fashion, AuNP-mediated DNA transfection efficiency was regulated by
controlling the intracellular glutathione level.82
The ligand-displacement rate by intracellular thiols (e.g. DHLA and GSH)
depends strongly on the monolayer structure and surface charge,83 allowing controlled
release of payload. As an example, Kotov et al. have demonstrated that AuNPs bearing 6mercaptopurine-9- -D-ribofuranoside significantly enhanced the anti-proliferative effect
against K-562 leukemia cells compared to the same drug in free form. 84 This
improvement was attributed to enhanced intracellular transport followed by the
subsequent GSH-mediated release in cytoplasm and lysosomes.
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Figure 1.6 (A) Schematic illustration of GSH-mediated surface monolayer exchange
reaction/payload release. (B) Fluorescence images of MEF cells displaying GSHcontrolled release of the fluorophore after incubation with 0, 5, and 20 mM GSH-OEt.
In a strategy that combines glutathione-mediated release with non-covalent
loading of drugs (vide infra), Kim et al. reported cyclodextrin-functionalized AuNPs as
carriers of anti-cancer drugs.85 The AuNPs used the cyclodextrin moieties to encapsulate
drugs, anti-epidermal growth factor receptor (anti-EGFR) antibody as a targeting moiety,
and poly(ethyleneglycol) (PEG) as an anti-fouling shell (Figure 1.7). The anticancer drug
-Lapachone, was efficiently encapsulated into the hydrophobic cavity of cyclodextrin
onto AuNPs and then released by intracellular GSH. The introduction of an anti-EGFR
antibody onto the AuNPs was shown to both enhance the uptake of AuNPs and increase
the degree of apoptosis.
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Figure 1.7 Schematic illustration of the functionalization of AuNP with -lapachone,
using: i) SH-CD and mPEG-SH for AuNP-1 (RhoCD and mPEG-SH for RhoCD-AuNP1); ii) SH-CD, mPEG-SH, and NHS-PEG-SH for AuNP-1.5 (RhoCD, mPEG-SH, NHSPEG-SH for RhoCD-AuNP-1.5) and iii) anti-EGFR.

1.4.2 Encapsulation of therapeutics in monolayer of gold nanoparticles
Non-covalent incorporation of drugs into AuNP monolayers provides an
alternative delivery strategy that allows direct use of unmodified drugs, thus avoiding
prodrug processing issues. Drug encapsulation with AuNPs relies on the use of ligands
that generate a hydrophobic interior to the monolayer. Structurally, the radial nature of
the monolayer results in a decrease in ligand density as one goes further from the core of
small AuNP cores (< ~6 nm).86 Consequently “hydrophobic pockets” are created inside
the monolayer of the AuNP into which hydrophobic materials can be partitioned.
Pasquato et al. demonstrated the encapsulation of radical probes in AuNP monolayers,
using EPR spectroscopy to monitor the partition of the lipophilic probe between
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monolayer of AuNP and bulk water. 87 As expected, smaller particles featuring more
strongly radial monolayers favor guest encapsulation (Figure 1.8).

Figure 1.8 (A) Schematic representation of AuNP and the nitroxide probe inclusion. (B)
Plot of the ratio between the concentration of 2 partitioned in the monolayer and that of
the free species ( 16 nm;  3.4 nm;  5.3 nm) as a function of [HS-C8-TEG] bound
to the gold.

The concept of monolayer encapsulation has recently been applied to drug
delivery. Rotello et al. have developed a biocompatible AuNP carrier that employs
hydrophobic pockets to encapsulate drugs and deliver them into cancer cells. 88 The
particles (~ 2.5 nm core) featured a hydrophobic alkanethiol interior and a hydrophilic
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shell composed of a tetra(ethylene glycol) (TEG) unit terminated with a zwitterionic
headgroup designed to minimize nonspecific binding with biomacromolecules 89 and
other cell surface functionality (Figure 1.9). Hydrophobic payloads were kinetically
entrapped in the monolayer, with the resulting host-guest materials stable in buffer and
serum. The entrapped payloads were released into cells by membrane-mediated diffusion,
as demonstrated by both fluorescence microscopy (using a fluorophore payload) and
through drug efficacy with therapeutic guests. No particle uptake was observed with
these systems using ICP-MS, making these systems excellent candidates for passive
targeting using the enhanced permeability and retention (EPR) effect.90

Figure 1.9 (A) Structure of particles and guest compounds: Bodipy, TAF, and LAP, the
number of encapsulated guests per particle (B) Cytotoxicity of AuNPZwit complexes
measured by Alamar blue assay after 24 h incubation with MCF-7 cells. IC50 of AuNP
(NP), equivalent drugs (Drug), and free drugs are shown in table.

16

Photodynamic therapy (PDT) is a promising strategy that uses reactive oxygen
species (ROS) to induce apoptosis or necrosis. Burda et al. reported the use of PEGylated
AuNP-Pc4 (Si-phthalocyanine) conjugates as efficient platforms for PDT (Figure 1.10
(a)).91 The phthalocyanine photosensitizing agent was encapsulated by the PEG ligands
through van der Waals interaction, with the PEG ligand inhibiting colloid aggregation
and providing significant resistance to non-specific binding with biomacromolecules. The
release of Pc4 from AuNP in vitro in a two-phase solution system and in vivo in cancerbearing mice (Figure 1.10 (b)) indicated that the delivery process was highly efficient,
with Pc4 preferentially accumulated in tumor sites. With the Au NP-Pc 4 conjugates, the
drug delivery time required for PDT was reduced from 2 days using the free drug to 2 h,
using the conjugate (Figure 1.10).
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Figure 1.10 (A) Sturcture of the water-soluble AuNPs as a PDT drug delivery agent, Pc 4
structure (B) Fluorescence images of a tumor-bearing mouse after being injected with Au
NP-Pc 4 conjugates in normal saline (0.9% NaCl, pH 7.2), (a) 1 min, (b) 30 min, and (c)
120 min after intravenous tail injection. Any bright signal is due to Pc 4 fluorescence. For
comparison, a mouse that got only a Pc 4 formulation without the AuNP vector injected
is shown in panel (d). No circulation of the drug in the body or into the tumor was
detectable 2 h after injection without the AuNP as a drug vector.

1.4.3 Light-regulated release of payload
The ability to regulate drug release is an important property for drug delivery
systems. While endogenous approaches such as GSH-mediated release provide very
useful strategies for delivery, externally controlled release provides a complementary tool
18

for site- and time-specific control of payload release.92 Recently, caged drugs have been
developed where the activity of the drug was suppressed by attaching it to a blocking
element through a photoremovable protecting group.93 Rotello et al. have applied this
strategy to AuNP delivery vehicles, utilizing a photo-cleavable o-nitrobenzyl ester moiety
that dissociates upon light irradiation to alter the surface potential from positive to
negative, thereby releasing adsorbed DNA. In more recent studies, the authors
demonstrated light-controlled release of anticancer drug (5-fluorouracil) from
nanoparticles (Figure 1.11).94 The AuNPs (Au_PCFU, Au core: ~2 nm) featured a mixed
monolayer of zwitterionic and photocleavable ligands. The zwitterionic ligand provided
solubility and prevented cellular uptake. The photocleavable ligand linked the
fluorouracil to the particle through an orthonitrobenzyl group that could be effectively
cleaved using near-UV irradiation (365 nm). An IC50 value of 0.7 M observed upon
irradiation for Au_PCFU on a per particle basis, whereas no significant cell death was
observed in cells treated with only light or only Au_PCFU.
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Figure 1.11 (A) Photochemical reaction (365 nm) of Au_PCFU and delivery of payload
to cell. (B) Cytotoxicity of different concentrations of Au_PCFU under uncaging
conditions. The IC50 value was 0.7 M per particle, 11.9 M per drug.
In related research, Nakanishi et al. have reported a photoresponsive nanocarrier
of amines, including cell signaling agents. (Figure 1.12).95 In this approach a carbamate
linkage could be dissociated via the photocleavage reaction of the 2-nitrobenzyl group
upon near-UV irradiation. The caging process was very effective: histamine had no
biological activity while it was attached to AuNPs but became active when it was
released from the particles upon photo-irradiation.

1.4.4 Other attachment/release strategies
A variety of additional delivery strategies have been developed using AuNP
platforms. Schoenfisch et al. have demonstrated that nitric oxide (NO) can be efficiently
released at acidic pH from gold nanoparticles, 96 providing a potential means of
controlling multiple cellular processes including angiogenesis, vasodilation, and the
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immune response.97 Hwu et al. have used a phosphate linker to conjugate paclitaxel to
AuNP and Fe3O4 particles. 98 The drug could be released from the particles using
phosphodiesterase.

Figure 1.12 Capture and release of amines on GNPs having a photocleavable
succinimidyl ester.

1.5 Dissertation overview
Engineering the interfaces between biomolecules and nanomaterials is important
for the creation of systems with potential applications in therapeutics. My research has
been oriented toward biotechnological applications in cancer therapy via engineering the
interface between biomacromolecules and nanomaterials. For the purpose, I have
employed a synergistic approach, combining materials, surface science, organic
synthesis, and biology to develop surface functionalized AuNPs with a tailored
monolayer. In the following chapters, details of designing functionalized AuNPs and
their use in therapeutic applications are described.
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Figure 1.13 Dissertation overview. Schematic illustration of therapeutic applications of
AuNPs described in this thesis.
In Chapter 2, AuNPs with non-covalent loading of drugs on the monolayer will be
discussed. Non-covalent incorporation of drugs into AuNP monolayers provides an
alternative delivery strategy that allows direct use of unmodified drugs, thus avoiding
prodrug processing issues. Hydrophobic payloads were kinetically entrapped in the
monolayer with the resulting host–guest materials stable in buffer and serum. Upon
incubation with cancer cells, the entrapped payloads were efficiently released into cells
by membrane-mediated diffusion without cellular uptake of the particles, showing
therapeutic efficiency. This system is an excellent candidate for passive targeting using
the enhanced permeability and retention effect.
Chapter 3 will discuss about pH-labile prodrugs incorporated AuNPs with
positive or negative surface charges to study diffusion of the payloads and their carrier in
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cylindroids tumor model. Anticancer drugs are attached on the AuNP surface through
acid-cleavable linkers, allowing pH induced drug release. Positively charged
nanoparticles improved delivery of payloads to the majority of cells in tumours, whereas
negatively charged particles would perform better when delivering drugs deep into
tissues. The ability to tune surface charge to control tissue penetration and drug release
makes gold nanoparticles a flexible and powerful drug delivery vehicle.
Chapter 4 will illustrate the recognition mediated activation of therapeutic AuNPs
through regulation of synthetic host-guest complexation process inside the living cell. We
will describe a supramolecular synthetic host-guest system featuring diaminohexane
terminated AuNPs (AuNP-NH2) and cucurbit[7]uril (CB[7]). In this system, threading of
CB[7] on the particle surface reduces the cytotoxicity of the AuNP-NH2 by sheathing the
lethal diaminohexane ligand. Intracellular triggering of the therapeutic effect of AuNPNH2 was achieved via the administration of 1-adamantylamine (ADA). ADA binds to
CB[7] with higher affinity than the diaminohexane ligand and thus removes CB[7] from
the nanoparticle surface. This intracellular disassembly of AuNP-NH2 and CB[7]
complex activates the in situ cytotoxicity of AuNP-NH2 and hence induced cell death.
This result presents a new strategy for triggering therapeutic systems through the use of
competitive interactions of orthogonally presented guest molecules.
In Chapter 5, regulating exocytosis of AuNPs by using host-guest chemistry will
be discussed. AuNPs featuring quaternary amine head groups were internalized into the
cells by endocytosis. Subsequent in situ treatment of a complementary cucurbit[7]uril
(CB[7]) to the amine head groups induced the particles-CB[7] complexation inside of the
cells, rendering the particles assembled each other. The larger induced particle assemblies
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remained sequestered in the endosomes, inhibiting exocytosis of the particles without any
observed cytotoxicity. This approach would provide a potential strategy for prolonged
retention of drug carriers within endosome, enabling sustained release of the loaded
therapeutics in the carriers.
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CHAPTER 2

ENTRAPMENT OF HYDROPHOBIC DRUGS IN GOLD NANOPARTICLE
MONOLAYERS WITH EFFICIENT RELEASE INTO CANCER CELLS

2.1 Introduction
Drug delivery systems (DDSs) provide an important tool for increasing efficacy
of pharmaceuticals through improved pharmacokinetics and biodistribution. 1 A wide
variety of nanoscale materials such as liposomes, polymeric micelles, and dendrimers,
have been employed as drug carriers.2 Both covalent and non-covalent approaches can be
applied to the conjugation of drugs into these DDSs.3,4 Non-covalent approaches have the
capability of employing active drugs, whereas covalent attachment generally requires
chemical modification which can cause reduced efficiency of drug release or incomplete
intracellular processing of a prodrug.5
Recently, gold nanoparticle (AuNP) based drug/gene delivery systems have
attracted attention due to their functional versatility,6 biocompatibility,7 and low toxicity,8
Recent studies have demonstrated controlled release of payload by intracellular thiols.9, 10,
11, 12, 13

However, controlled dissociation of drugs in active form from covalent AuNP-

drug conjugates remains a challenge for clinical applications.2
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2.1.1 Non-covalent loading of the drugs on gold nanoparticles
Non-covalent incorporation of drugs into AuNP monolayers provides an
alternative delivery strategy with the potential for avoiding drug release and prodrug
processing issues. The structure of commonly used water-soluble AuNPs is similar to that
of unimolecular micelles such as dendrimers, featuring a hydrophobic interior and a
hydrophilic exterior (Figure 2.1). 14 The alkanethiol monolayer of the nanoparticle
coupled with the radial nature of the ligands 15 creates “hydrophobic pockets” inside
monolayer of AuNP where organic solutes can be partitioned, as demonstrated by
Lucarini and Pasquato.16 We report here the use of these pockets to encapsulate drugs and
deliver them with high efficiency to cells. This work has been reported as a
communication in the Journal of the American Chemical Society.17
The biocompatible AuNPs used in this study feature two functional domains: a
hydrophobic alkanethiol interior and a hydrophilic shell composed of a tetraethylene
glycol (TEG) unit terminated with a zwitterionic headgroup. Particles with this general
structure have been shown to minimize non-specific binding with biomacromolecules.18,
19

Figure 2.1 Delivery of payload to cell through monolayer-membrane interactions.
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2.2 Results and discussion
2.2.1 Loading of drugs/dyes in the monolayer of gold nanoparticles
We chose three different hydrophobic guest compounds: 4,4-difluoro-4-bora3a,4a-diaza-s-indacene (Bodipy) as a fluorescent probe, 20 and the highly hydrophobic
therapeutics tamoxifen (TAF) and -lapachone (LAP) as drugs (Figure 1). The
nanoparticle-payload conjugates (AuNPZwit-Bodipy, TAF, and LAP) were prepared by
the solvent displacement method.21 First, AuNPZwit (Au core: 2.5 ± 0.4 nm) and guest
were dissolved in an acetone/water mixture and the solvent slowly evaporated. The bulk
of the excess guest precipitated out and was removed by filtration; the particles were
further purified by multiple filtrations through a molecular weight cutoff filter until no
free guest was observed, followed by dialysis against buffer. The number of entrapped
guest molecules per particle was determined from 1H NMR spectrum and NaCN-induced
decomposition experiments and varied depending on size, hydrophobicity (logP), and
molecular structure of hydrophobic molecules (Figure 2.2). The particle/guest complexes
are stable in buffer for >1 month and to extended dialysis, a level of kinetic entrapment
greater than that observed with dendrimers.

40

Figure 2.2 Structure of particles and guest compounds: Bodipy, TAF, and LAP, and the
number of encapsulated guests per particle.

2.2.2 Stability of gold nanoparticles-payloads
The ability of the delivery systems to release their payload was first explored
using AuNPZwit-Bodipy in a two-phase dichloromethane (DCM)-water system. In this
system the dye is quenched by the AuNP, and photoluminescence (PL) only observed
upon dye release. In these studies a rapid increase in PL intensity is observed along with
transfer of Bodipy into the DCM layer (Figure 2.3 (a)). Significantly, since no release is
observed in monophasic aqueous conditions and no particle was observed in the DCM
layer, payload release presumably occurs via a particle-interface process.
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Figure 2.3 a) Release of Bodipy from AuNPZwit-Bodipy in DCM-aqueous solution twophase systems (ex= 499 nm, em= 517 nm) b) PL intensity AuNPZwit-Bodipy in cell
culture medium and 100 % serum, indicating little or no release relative to AuNPZwitBodipy in PBS after NaCN-induced release of guest molecules (ex= 499 nm, em= 510
nm).

2.2.3 Cellular uptake of the gold nanoparticles and their payloads
Payload delivery to cells using AuNPZwit-Bodipy was determined by confocal
laser scanning microscopy (CLSM) using human breast cancer (MCF-7) cells. Efficient
delivery of the dye to the cytosol is observed after 2 h incubation with AuNPZwit-Bodipy
(Figure 2.4 (a)-(c)). Cellular uptake of nanoparticle was studied using transmission
electron microscopy (TEM), and inductively coupled plasma mass spectrometry (ICPMS), using the analogous cationic particle/dye conjugate AuNPTTMA-Bodipy as a
positive control. Little or no cellular uptake of AuNPZwit was observed by either TEM
(Figure 2.4 (d) and (e)) or ICP-MS (Figure 2.4 (f)) for AuNPZwit-Bodipy, whereas
substantial particle uptake was observed with AuNPTTMA-Bodipy Since no free dye
was observed during the 24 h incubation of AuNPZwit-Bodipy in medium and serum
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solution at 37 ºC (Figure 2.3 (b)), Bodipy delivery presumably occurs via a monolayermembrane transfer process, consistent with our in vitro studies. 22

Figure 2.4 CLSM images of MCF-7 cell treated with AuNPZwit-Bodipy for 2h: (a)
green channel (b) bright field, and (c) overlap. TEM images of fixed cell treated with (d)
AuNPZwit-Bodipy and (e) AuNPTTMA as a positive control, Endosomally trapped
AuNPs are marked by arrow. (f) ICP-MS measurement. (200,000 cells/well), NPZwit:
AuNPZwit-Bodipy and NPTTMA: AuNPTTMA-Bodipy) indicating little cellular uptake
of nanoparticle with AuNPZwit-Bodipy.
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2.2.4 Delivery of the anticancer drugs into the cancer cells
Demonstration of drug delivery to MCF-7 cells was determined through
cytotoxicity studies of free and encapsulated drugs using an Alamar blue assay (Figure
2.5). Notably, AuNPZwit itself was non-toxic at 30 M. In contrast, IC50 values of 4 µM
and 4.6 µM were observed using AuNPZwit-LAP and AuNPZwit-TAF, respectively. The
delivery process was quite efficient, with the per drug molecule IC50 of AuNPZwit-TAF
(46 µM) only three-fold higher than that of TAF (16 M), and that of AuNPZwit-LAP
(6.0 µM) essentially identical to that of LAP (5.2 M).

Figure 2.5 Cytotoxicity of AuNPZwit complexes measured by Alamar blue assay after
24h incubation with MCF-7 cells. IC50 of AuNP (NP), equivalent drugs (Drug), and free
drugs are shown in table.
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2.3 Summary and future outlook
In conclusion, we have demonstrated that hydrophobic dyes/drugs can be stably
entrapped in the hydrophobic pocket of AuNPs and released into cell by membranemediated diffusion without uptake of the carrier nanoparticle. Importantly, the small size
of these nanocarriers coupled with their biocompatible surface functionality should
provide long circulation lifetimes and preferential accumulation in tumor tissues by the
enhanced permeability and retention (EPR) effect. 23 Additionally, the non-interacting
nature of their monolayer should make these systems highly amenable to targeting
strategies.

2.4 Synthesis of materials and experimental methods
General
Dichloromethane (DCM) used after distillation under CaCl2 and other chemicals from
Aldrich were used as received. Dimethylamine, 1,3-Propanesulfone, trifluroacetic acid
(TFA), triisopropylsilane (TIPS), and tamoxifen (TAF) were purchased from Aldrich.
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene

(Bodipy),

β-lapachone

(LAP),

and

AuNPTTMA were prepared by the literature procedures.24, 25, 26 Theramanox® coverslips,
uranyl acetate, osmium tetroxide, glutaraldehyde, lead citrate, epoxy embedding kit (Low
Viscosity, as reported by Dr. Spurr) and 300 mesh copper grids with carbon film were
purchased from Electron Microscopy Sciences.
1

H and 13C NMR spectra were recorded on a Bruker AVANCE 400 at 400 and 100 MHz,

respectively. ESI-MS spectra were obtained using JEOL MStation JMS700. UV-vis
spectra were recorded on Hewlett-Packard 8452A spectrophotometer. Photoluminescence
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spectrum was

measured

using

Photon

Technology

International

fluorescence

spectrometer. Dynamic light scattering (DLS) was measured by Zetasizer Nano ZS.
Fixed cell sections for TEM were cut by using Reichert Ultracut E Ultramicrotome and
imaged using JEOL 100S electron microscopy. Cell viability using Alarmar blue assay
was assessed by SpectraMax M5 microplate spectrophotometer and plotted by Origin 8.
Fluorescence images was obtained using Zeiss LSM510 meta confocal microscope.

2.4.1 Synthesis of ligand and fabrication of nanoparticle

Figure 2.6 Synthesis of HS-C11-TEG-Zwit. (a) Dimethylamine, DCM, RT, overnight (b)
1,3-Propanesulfone, acetone, RT, overnight, (c) TFA, TIPS, RT, 4h
Compound 2
Compound 1 (1 g, 1.4 mmol) was added to a solution of dimethylamine (0.6 g, 14 mmol
in dichloromethane (20 mL) and the reaction mixture was stirred at room temperature for
overnight. The reaction mixture was poured into a mixture of dichloromethane and
distilled water. Organic layer was separated and concentrated at reduced pressure. The
crud product was purified by column chromatography over silica gel using hexane/ethyl
acetate (1:4, v/v) as an eluent. Solvent was removed in vacuo to afford compound 2 as
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colorless oil (Yield 0.6 g, 65 %). 1H NMR (400 MHz, CDCl3)  7.41 (m, 6H, Ph-), 7.27
(m, 6H, Ph-), 7.20 (m, 3H, Ph-), 3.65-3.56 (m, 14H, -CH2-TEG-), 3.44 (t, J = 6.8 Hz, 2H
-OCH2-CH2-N(CH3)2), 2.53 (t, J = 5.8 Hz, 2H, -OCH2-CH2-N(CH3)2), 2.84 (s, 6H, N(CH3)2), 2.14 (t, J = 7.3 Hz, 2H, -S-CH2-), 1.40 (m, 18H, -S-CH2-(CH2)9-);

13

C NMR

(100.64 MHz, CDCl3)  26.10, 28.60, 29.02, 29.19, 29.41, 29.48, 29.56, 29.65, 32.04,
45.81, 58.77, 66.36, 69.23, 70.07, 70.40, 70.61, 71.55, 126.49, 127.79, 129.62, 145.10.
Compound 3
A anhydrous acetone solution (20 mL) of compound 2 (0.5 g, 0.77 mmol) and 1,3propanesultone (0.14 g, 1.15 mmol) in anhydrous acetone was stirred at room
temperature for overnight. The reaction mixture was filtered, and the resulting solid was
washed with ethyl acetate/hexane (1:4, v/v) and dried in vacuum to afford compound 3 as
a white solid (Yield 0.5 g, 84 %). 1H NMR (400 MHz, CDCl3)  7.41 (m, 6H, Ph-), 7.27
(m, 6H, Ph-), 7.20 (m, 3H, Ph-), 3.94 (m, 2H, -OCH2-CH2-N(CH3)2-), 3.78 (m, 2H, OCH2-CH2-N(CH3)2-), 3.71-3.56 (m, 14H, -CH2-TEG- and -CH2-CH2-CH2-sulfonate),
3.42 (t, J = 6.8 Hz, 2H, -OCH2-CH2-N(CH3)2-), 3.23 (s, 6H, -N(CH3)2-), 2.88 (t, J = 6.7
Hz, 2H, -CH2-CH2-CH2-sulfonate), 2.26 (m, 2H, -CH2-CH2-CH2-sulfonate), 2.12 (t, J =
7.3 Hz, 2H, -S-CH2-), 1.40 (m, 18H, -S-CH2-(CH2)9-); MS (ESI-MS) calcd for
C43H66NO7S2 773.12, found 794.6 [M+Na]+

HS-C11-TEG-Zwit
A dichloromethane solution of compound 3 (0.6 g, 0.77 mmol), trifluoroacetic acid (1.78
g, 16 mmol), and triisopropylsilane (0.18 g, 1.1mmol) was stirred at room temperature for
6 h under argon. After removal of the solvent at reduced pressure, the residue was
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purified by washing with diethyl ether (20 ml x 5). After drying residue under high
vacuum, white solid of product was obtained. (Yield 0.36 g,87 %) 1H NMR (400 MHz,
CDCl3) 3.91 (m, 2H, -OCH2-CH2-N(CH3)2-), 3.79-3.52 (m, 16H, OCH2-CH2-N(CH3)2-, CH2-TEG-, and -CH2-CH2-CH2-sulfonate), 3.42 (t, J = 6.8 Hz, 2H, -OCH2-CH2-N(CH3)2), 3.41 (t, J = 6.8 Hz, 2H, -OCH2-CH2-N(CH3)2-), 3.04 (s, 6H, -N(CH3)2-), 2.90 (brs, 2H,
-CH2-CH2-CH2-sulfonate), 2.49 (q, J=7.2 Hz, 2H, HS-CH2-), 2.26 (brs, 2H, -CH2-CH2CH2-sulfonate), 1.40 (m, 18H, -S-CH2-(CH2)9-); MS (ESI-MS) calcd for C24H52NO7S2
530.32, found 552.4 [M+Na]+.

Preparation of AuNPZwit
Gold nanoparticles, C5 NP were prepared by following the Brust-Schiffrin two-phase
method using 1-pentanethiol as capping ligands. To fabricate AuNPZwit via ligand place
exchange reaction, 30 mg of C5 NP were mixed with 100 mg of HS-C11-TEG-Zwit in
dichloromethane (10 mL). The solution was stirred at room temperature for 24 hours.
Solvent was removed by rotary evaporator and the nanoparticles were washed with
diethyl ether (20 mL x 5). The nanoparticles were further purified by dialysis in MiliQ
water using SnakeSkin pleated dialysis tubing (10,000 MWCO) for 1days. 1H NMR
spectrum is shown in Figure 2.8 (a).

Figure 2.7 Synthetic pathway of AuNPZwit.
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2.4.2 Experimental methods
Preparation and characterization of AuNPZwit complexes (AuNPZwit-dye/drug
conjugates)
In order to prepare AuNPZwit complexes, solvent displacement method was carried out
using water and acetone. An acetone solution of each guest compound (10 mg) and
aqueous solution of AuNPZwit (80 M) were well mixed. Acetone was then removed by
rotary evaporator or slow evaporation at room temperature. During the evaporation of
acetone, some guest compounds were entrapped in interior of AuNPZwit due to
hydrophobic interaction and the rest of guest compounds were precipitated out. The
mixture was then filtrated using filter (0.2 m pore) to remove the precipitate. Any
residue of free guest compounds in the aqueous solution may affect to result of
cytotoxicity and fluorescence related experiments. For further purification, the
AuNPZwit complexes solution was washed with distilled water and centrifuged with
Amicon Ultra-4 tube (10,000 MWCO) several times (2 mL x ~5 times) until no
absorbance of guest molecules in filtrate was detected by spectrophotometer.
AuNPTTMA-Bodipy was also prepared by the same procedure.
AuNPZwit complexes conjugates were characterized by nuclear magnetic resonance
(NMR). 1H NMR spectrum of AuNPZwit complexes are shown in Figure 2.8 (b)-(d). A
broaden of 1H NMR peak of the guest compounds indicates that guest compounds were
entrapped in hydrophobic pocket of the AuNPZwit. It is also noted that the H1 NMR peak
of guest compounds (TAF and Bodipy) in D2O was not present until AuNPZwit complex
was formed. The stoichiometry of the AuNPZwit complexes was calculated by measuring
integral of AuNPZwit and guest compounds. From TGA and TEM analysis, it is
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estimated that 100 ligands are placed on each AuNPZwit.27 Around 10~11 TAFs were
entrapped in AuNPZwit. The number of entrapped guest compounds for AuNPZwit-LAP
and AuNPZwit-Bodipy were calculated from the NaCN-induced decomposition
experiment due to weak 1H NMR signal of guest compound.
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Figure 2.8 1H NMR spectrum of AuNPZwit and AuNPZwit complexes (a) AuNPZwit
(b) AuNPZwit-TAF, (c) AuNPZwti-LAP, (d) AuNPZwit-Bodipy.

NaCN-induced decomposition of AuNPZwit complexes
To 1 ml of a solution of the desired AuNPZwit complexes in THF (final concentration
of 0.5 ~ 4 μM) was added 1 mL of an aqueous NaCN solution (final concentration 0.1 M)
followed by briefly agitating the mixture. After 2 h, plasmon absorption band of the
AuNP at 520 nm completely decayed while absorbance of guest compounds remained.
Concentration of guest compounds was then calculated based on the Beer-Lambert law
(λmax = 496 nm for Bodipy, λmax = 290 nm for LAP, and λmax = 280 nm for TAF). By
comparing with the concentration of AuNPZwit before etching, the number of guest
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compounds entrapped in AuNPZwit was estimated. A molar extinction coefficient of free
guest compounds in THF/H2O (1:1) was obtained for this estimation (Bodipy ε = 7.07 x
103 at 496 nm, LAP ε = 1.2 x 104 at 290 nm, and TAF ε = 1.1 x 104 at 280 nm).

Figure 2.9 UV-vis spectrum of AuNPZwit complexes before and after NaCN-induced
decomposition experiment. (a) AuNPZwit-TAF, (b) AuNPZwit-LAP, and (c) AuNPZwitBodipy.
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Stability test of AuNPZwit complexes in PBS
1 mL of AuNPZwit complexes (5 μM) in PBS was centrifuged with Amicon Ultra-4
tube (10,000 MWCO) at 8,000 rpm for 30 min. Stability of AuNPZwit complexes was
examined by measuring the absorbance of the filtrate. Any absorbance of guest
compound in filtrate was not observed at least for one month.

Partition Coefficient logP
Partition coefficient, logP was obtained according to our previous study.28 The logP for
the hydrophobic compounds as followings: LAP: 2.68, TAF: 3.64, and Bodipy: 4.0. It
indicates that LAP is less hydrophobic than TAF and Bodipy, which might cause the
lower number of encapsulated guests in AuNPZwit.

Cell culture
MCF-7 cells were grown in a cell culture flask in low glucose Dulbecco's Modified
Eagle Medium supplemented with 10% fetal bovine serum (FBS) and 1 % of antibiotics
at 37 °C in a humidified atmosphere of 5 % CO2.

Cytotoxicity test of AuNPZwit complexes
MCF-7 cells were seeded at 20,000 cells in 0.2 ml per well in 96-well plates 24 h prior
to the experiment. The old medium were replaced by different concentrations of TAF,
LAP, AuNPZwit-TAF, AuNPZwit-LAP, and AuNPZwit in serum containing medium
and incubated for 24 h at 37 °C in a humidified atmosphere of 5 % CO2. The cells were
then completely washed with PBS buffer three times and 10 % Alarmar blue of serum
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containing medium was added to each well and further incubated at 37 ºC for 3 h. The
cell viability was then determined by measuring the fluorescence intensity at 570 nm
using a SpectraMax M5 microplate spectrophotometer. Curves were fitted by DoseRep
function in Origin 8.

Confocal laser scanning microscopy
MCF-7 cells were seeded in 35 mm Petri dish (Mat Tek Corporation, MA) at 50,000
cells in 1 mL of serum containing medium 24 h prior to the experiment. The medium was
replaced by serum containing medium and AuNPZwit-Bodipy to a final concentration of
1 μM and were incubated for 2 h. Cells were washed with PBS three times before being
imaged under a confocal microscope (Zeiss LSM510 meta confocal microscope equipped
with an argon-HeNe laser, λex = 488 nm).

ICP-MS Instrumentation
All ICP-MS measurements were performed on a Perkin Elmer Elan 6100. Operating
conditions of the ICP-MS are listed below: RF power: 1200 W; plasma Ar flow rate: 15
L/min; nebulizer Ar flow rate: 0.96 L/min; isotopes monitored: 197Au; dwell time: 50 ms;
nebulizer: cross flow; spray chamber: Scott.

ICP-MS sample preparation and measurements29
AuNPZwit-Boidpy and AuNPTTMA-Bodipy (1 M) was incubated with pre seeded
MCF-7 cell line in 24 well plates (200,000 cells/well) for 4h and 24 h (Figure 2.10). After
incubation and lysing the cells, the resulting cell lysate was digested overnight using 3
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mL of HNO3 and 1 mL of H2O2. On the next day, 3 mL of aqua regia, which is highly
corrosive and must be use with extreme caution, was added, and then the sample was
allowed to react for another 2-3 h. The sample solution was then diluted to 100 mL with
de-ionized water, and aqua regia. The final AuNP sample solution contained 5% aqua
regia. The AuNPs sample solution was measured by ICP-MS under the operating
conditions described above. Cell uptake experiments with each AuNP were repeated 3
times, and each replicate was measured 5 times by ICP-MS. A series of gold standard
solutions (20, 10, 5, 2, 1, 0.5, 0.2, 0 ppb) were prepared before each experiment. Each
gold standard solution contained 5% aqua regia. Each standard solution was also
measured 5 times by ICP-MS using the operating conditions described above. The
resulting calibration line was used to determine the gold amount in taken up by the cells
in each sample. A ~100 ppm solution of dithiothreitol was used to wash the instrument
between analyses to facilitate gold removal.
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Figure 2.10 ICP-MS measurement of AuNPZwit-Boidpy and AuNPTTMA-Bodipy for 4
and 24 h.
TEM preparation for AuNPZwit complexes and fixed cell treated with AuNPs
MCF-7 cells were seeded and incubated on 15 mm diameter Theramanox® coverslips
(Nalge Nunc International, NY) placed in 24 well plates at amount of 100,000 cells in 1
ml of serum containing medium for 24 h prior to the experiment. The medium was
replaced by 1 ml of serum containing medium and AuNPZwit-Bodipy or AuNPTTMA to
a final concentration of 1 μM and incubated for 4 h.30 The medium containing the gold
nanoparticles not taken up by the cells was discarded, and the cells were completely
washed with PBS buffer three times. The cells were then fixed in 2 % glutaraldehyde
with 3.75 % sucrose in 0.1 M sodium phosphate buffer (pH 7.0) for 30 min and then
washed with 0.1 M PBS containing 3.75% sucrose three times over 30 min. They were
postfixed in 1 % osmium tetroxide with 5 % sucrose in 0.05 M sodium phosphate buffer
solution (pH 7.0) for 1 hr and the rinsed with distilled water three times. They were
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dehydrated in a graded series of acetone (10 % step), and embedded in epoxy resin. The
resin was polymerized at 60 °C for 48 h. Ultrathin sections (50−70 nm) obtained with a
Reichert Ultracut E Ultramicrotome were stained with 2% aqueous uranyl acetate and 2%
aqueous lead citrate and imaged under a JEOL 100S electron microscopy.
TEM samples of AuNPZwit and AuNPZwit complexes were prepared by placing one
drop of the desired AuNP solution (3 μM) on to a 300-mesh Cu grid coated with carbon
film. These samples were analyzed and photographed using the same instrument. TEM
image of AuNPZwit is shown in Figure 2.11 (a). The average diameter of Au core is 2.5
± 0.4 nm.

Figure 2.11 (a) TEM images of AuNPZwit. (b) UV-vis spectrum of AuNPZwit and
AuNPZwit complexes. No red shift of plasmon absorption band was observed.
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Thermogravimetric analysis (TGA)
TGA was performed using a TGA 2950 high-resolution thermo-gravimetric analyzer
(TA Instruments, Inc., New Castle, DE), which was equipped with an open platinum pan
and an automatically programmed temperature controller. The TGA data were obtained
as follows: about 3.0 mg of AuNPZwit was placed in the TGA pan and heated in a
nitrogen atmosphere at a rate of 10 °C / min up to 600 °C. TGA curve of AuNPZwit is
shown in Figure S5. The TGA data showed that the weight percentage of organic ligands
and Au core of AuNPZwit is 35 % and 65 %, respectively. Accordingly, the average
number of the lignads is estimated as ~100, which is comparable to the literature.31

Figure 2.12 Thermal gravimetric analysis (TGA) data of AuNPZwit.
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CHAPTER 3

TUNING PAYLOAD DELIVERY IN TUMOR CYLINDROIDS USING GOLD
NANOPARTICLES

3.1 Introduction
Inefficient delivery limits the efficacy of many chemotherapeutic treatments.1, 2, 3,
4, 5

Overcoming delivery limitations requires precise control of interstitial diffusion and

cellular uptake. Tumors typically have irregularly formed vasculature, with large
intervessel distances and heterogeneous populations of cells.6 These populations are often
unresponsive to standard therapy because of their distance from blood vessels and
resistance to molecular uptake.7 This limited efficacy prevents complete cell clearance
per drug cycle, which can eventually lead to tumor regrowth, metastatic disease and poor
treatment outcomes.8, 9
Colloidal gold nanoparticles have great potential to overcome delivery limitations
because of their biocompatibility, low toxicity, small size and tunable surface
functionalities. 10 ,

11

Functionality can be tuned by modifying the composition of

functional molecules in the mixed monolayer on the surface of gold nanoparticles. 12, 13, 14
In cancer cell cultures, surface properties have been shown to regulate cellular uptake,
intracellular release and distribution in subcellular compartments.15, 16, 17, 18 Modification
of the surface properties of gold nanoparticles therefore has the potential to control
accumulation in tumors, and the locations at which drug payloads are released.
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Three-dimensional in vitro tumor models provide an important tool for the
optimization of efficient intratumoral drug delivery. Multicellular tumor cylindroids
provide a unique platform with which to systematically monitor extracellular diffusion,
cellular uptake and molecular release from nanoparticles in real time (Figure 3.1a).
Tumor cylindroids are spheroids constrained between two parallel surfaces. 19 , 20 The
geometry of cylindroids allows only radial diffusion from the peripheral edge to the
centre, simplifying analysis. Through the optically accessible cross-section, local
concentrations of nanoparticles and dyes can be measured with standard fluorescence
microscopy. Importantly, cylindroids consist of heterogeneous cell populations arranged
relative to their distance from the peripheral edge: cells in the periphery are
predominantly proliferating, and cells in the centre are mostly apoptotic and necrotic. 21, 22,
23

This radial organization mimics the distribution of cells around blood vessels in tumors

in vivo (Figure 3.1b).24, 25
We predict that different surface charges can control the penetration of
nanoparticles and the location of cellular uptake and release. Thioalkylated fluoresceinlabelled gold nanoparticles (2 nm core diameter, 6 nm overall with ligand) with positive
and negative surface charges were synthesized (Figure 3.1c) and administered to
cylindroids. Fluorophore concentrations were measured as functions of time and radial
position. The diffusion of gold nanoparticles in an extracellular matrix (Matrigel) was
measured in a linear cell free chamber. A mathematical model was developed to
discriminate between fluorescence from particles and released fluorescein, and to
calculate the rates of cellular uptake/release (Figure 3.1d) as a function of position in the
cylindroids. The determined parameters were used to predict the dynamics of particle
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transport and release from blood vessels in a conceptualized tumor (Figure 3.1b). Positive
and negative gold nanoparticles conjugated with doxorubicin (DOX) were similarly
synthesized, and our results show that surface charge can be used to control tissue
penetration and drug release. This work has been reported as an article in Nature
Nanotechnology.26

Figure 3.1 Schematic showing the delivery of payload by gold nanoparticles. (a)
Delivery of payload (green ovals) into tumor cylindroids by gold nanoparticles. Cells
containing released FITC–SH are in green. Viable cells are shown with smooth, solid
boundaries, and necrotic cells have irregular, dashed boundaries. Dashed arrows indicate
diffusion and cellular uptake. In cylindroids, nanoparticles are present in the medium
outside the boundary of the cell mass. (b) Intratumoral delivery by gold nanoparticles
following extravasation from the vessel lumen (red circles). (c) Mixed monolayerprotected gold nanoparticles loaded with thioalkylated FITC or doxorubicin (DOX). (d)
Cellular uptake and FITC–SH release by thiol-mediated replacement reactions.
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3.2 Results and discussion
3.2.1 Uptake of fluorescent gold nanoparticles
Nanoparticles were synthesized with gold cores protected by mixed monolayers27
to provide tunable probes for delivery. The monolayers on these particles consisted of
thioalkylated fluorescein isothiocyanate (FITC–SH) and either thioalkyl tetra(ethylene
glycol) lyated trimethyl ammonium or thioalkyl tetra(ethylene glycol)-lyated carboxylic
acid to create cationic (p-FITC–AuNP) and anionic (n-FITC–AuNP) gold nanoparticles
(Figure 3.1c), respectively.28 The surface zeta potentials of p-FITC–AuNP and n-FITC–
AuNP were measured to be + 30 and - 36 mV, respectively. The fluorescence intensities
of p-FITC–AuNP, n-FITC–AuNP and free fluorophore (FITC–SH) were used to calibrate
the fluorescence intensity and determine the FITC-SH loading ratio on each gold core.
Fluorescence intensities were linearly proportional to concentration (Figure 3.2a).
Conjugation to gold cores quenches FITC–SH fluorescence. Treatment with potassium
cyanide to recover quenched fluorescence increased the intensities of the p-FITC–AuNP
and n-FITC–AuNP solutions by factors of 4 and 2.4, respectively (Figure 3.2a). The ratio
of released ligand to free ligand fluorescence indicates that the loading ratios were 7.5
and 8.3 for p-FITC–AuNP and n-FITC–AuNP, respectively. The linear relationship
between intensity and concentration indicates that self-quenching did not have a large
effect over this concentration range.
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Figure 3.2 Fluorescence calibration and cellular uptake and release of FITC–AuNPs. (a)
Normalized fluorescence intensities plotted against nanoparticle concentration. Dotted
lines represent linear least-squares fitting results. For all components, fluorescence
intensity was linearly proportional to concentration. (b) and (c) Differential interference
contrast (DIC) and confocal green fluorescent images of cells in monolayer culture
incubated with cationic (b) and anionic (c) gold nanoparticles. Scale bars, 50 mm.

In monolayer cell culture, all FITC–SH release from nanoparticle core was
intracellular (Figure 3.2b and c). Intracellular release of FITC–SH is mediated by
cytoplasmic thiol compounds, of which reduced glutathione (GSH) is the most abundant.
29

Similar selectivity would be observed in vivo, because the intracellular concentration of

glutathione (1–10 mM) is considerably higher than that in plasma (2 µM). 30, 31 After
removal of media containing FITC–AuNP, stronger green fluorescence was observed
across the cells treated with p-FITC–AuNP (Figure 3.2b) compared with n-FITC–AuNP
(Figure 3.2c). This observation indicates that cellular uptake and dissociation were
greater for cationic gold nanoparticles, potentially mediated by interactions of the
particles with serum proteins. Cellular uptake and release in cylindroids was dependent
on particle surface charge and radial position (Figure 3.3). Intra- and extracellular
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fluorescence was measured in cylindroids in real time using fluorescence microscopy
(Figure 3.3a,c, and e). A clear morphological boundary could be observed between the
inner and outer regions of the cylindroids (Figure 3.3a, c, and e), which have been shown
to contain viable and apoptotic microenvironments, respectively. In the outer region,
cationic particles produced more fluorescence than free FITC and anionic particles
(Figure 3.3a–f). For positive particles, the fluorescence intensity in the outer region
increased with time, and eventually the entire cylindroid became fluorescent (Figure 3.3a
and b). For negative particles, the fluorescence intensity in the outer region did not
increase (Figure 3.3c) and remained unchanged after 11 h (Figure 3.3d). This preferential
uptake of cationic gold nanoparticles by proliferating cells was similar to the difference
observed in the monolayer cultures (Figure 3.2b,c). In the inner region, fluorescence
appeared at earlier time points than in the outer region and appeared regardless of surface
charge (Figure 3.3a–d). Images acquired at 4 and 8 h were spatially similar but fainter
than those at 11 h. In cylindroids incubated with free FITC, strong fluorescence appeared
only in the inner region (Figure 3.3e), and the intensity profiles remained unchanged for
11 h after treatment (Figure 3.3f). The enhanced cellular uptake of positive particles by
proliferating cells may be caused by electrostatic interaction with the net negative surface
charge of the plasma membrane, 32, 33 which has also been observed in liposomal and
polymeric delivery systems. 34 , 35 , 36 Particle charge had a pronounced effect on the
dynamics of particle uptake and fluorophore release (Figure 3.3g and h). These dynamics
were observed by averaging the behavior in the inner and outer regions, which were
defined as annuli 175–200 mm from the centre and 25–50 mm from the periphery of
three cylindroids (grey bars in Figure 3b and d).
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Figure 3.3 Release of FITC–SH from AuNPs in tumour cylindroids. (a)–(f), Green
fluorescence images ((a), (c), and (e)) and corresponding intensity profiles ((b), (d), and
(f)) of cylindroids treated with nanoparticles. Fluorescence images were acquired after
incubation with p-FITC–AuNP (a), n-FITC–AuNP (c) and FITC (e) for 11, 21 and 46 h.
Dotted circles indicate cylindroid edges. Scale bar, 300 mm. Fluorescence intensity
profiles are shown at 11, 21, 38 and 46 h ((b) and (d)). (g) and (h), Change of average
fluorescence intensities over time in the inner and outer regions of the cylindroids
(indicated by grey bars in (b) and (d)) after incubation with p-FITC–AuNP (g) and nFITC–AuNP (h). Errors are standard error of the mean (n=3). (i) Blue fluorescence image
of a cylindroid incubated with OPA for 18 h. Scale bar, 200 mm. (j) Green confocal
fluorescence microscope image of the outer region of the cylindroid treated with p-FITC–
AuNP. Scale bar, 20 µm.

In cylindroids treated with positive particles, fluorescence intensities increased
monotonically (Figure 3.3g). The behavior was considerably different for cylindroids
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treated with negative particles, in which the fluorescence intensity saturated with time
and eventually reached a plateau (Figure 3.3h). Comparing inner and outer regions, the
time-dependent behavior of cellular uptake/release was functionally similar for both
particle types (Figure 3.3g and h). Two possible causes for the early appearance of
fluorescence at the centre of the cylindroids following nanoparticle administration
(Figure 3.3a–d) can be suggested: first, an increased rate of uptake by apoptotic/necrotic
cells or, second, an increased rate of fluorophore dissociation due to higher thiol
concentrations. The dye o-phthaldialdehyde (OPA) reacts non-enzymatically with amino
acids and their derivatives in the presence of thiol compounds; this has been widely used
to measure intracellular glutathione concentration.37, 38 Staining with OPA showed that
the concentration of thiol compounds was higher in the outer region and decreased
toward the centre of the cylindroids (Figure 3.3i). This location of cellular thiol
compounds was opposite to the pattern of fluorescence from nanoparticles (Figure 3.3a–
d). We have previously shown that centers of cylindroids are composed of apoptotic and
necrotic cells and these cells preferentially take up particles when compared to viable
cells because they have lost membrane integrity. Together, these observations
demonstrate that cellular uptake is the dominant mechanism. If dissociation, and not
uptake, were the limiting mechanism, then fluorescence from released fluorophore would
have been greater in the periphery than in the centre. Ligand dissociation was expected to
be entirely intracellular because of the higher levels of glutathione relative to the
extracellular environment. Confocal microscopy was used to verify that extracellular
dissociation did not occur (Figure 3.3j). Following incubation with nanoparticles for 36 h,
FITC–SH release was observed primarily inside cells (Figure 3.3j). Intracellular
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localization of dissociation was consistent across the diameter of the cylindroids;
fluorescence was observed only inside cells in both the inner and outer regions.
Furthermore, the observed fluorescence patterns were conserved in the z-direction (away
from the objective), supporting the use of epifluorescent microscopy for quantitative
penetration measurements.

3.2.2 Uptake of doxorubicin nanoparticles
To further probe the potential therapeutic applications of engineered
nanoparticles, we fabricated particles featuring a doxorubicin prodrug tethered through an
acid-labile hydrazone linkage to a thiol ligand (Figure 3.1c). Similar to FITC–AuNP, a
positive surface charge dramatically enhanced uptake of DOX–AuNP into proliferating
peripheral cells when compared to negative particles and free drug (Figure 3.4). In
cylindroids, positive particles delivered more doxorubicin than negative particles (Figure
3.4a and b). With regard to position, positive particles delivered significantly more
doxorubicin to viable cells in the cylindroids periphery when compared to negative
particles and free drug, which were preferentially taken up by dead cells at the
cylindroids centre (P < 0.05; Figure 3.4d). This charge-dependent localization was
consistent over the 46 h of the experiment (P < 0.05; Figure 3.4e), during which the
concentration of particles and free drug increased within the cylindroids (Figure 3.4a–c,
radial profiles). The similarity of these results with the FITC results (Figure 3.3) supports
the prediction that nanoparticles with positive surface charges will outperform negative
particles for most applications, and confirms that charged gold nanoparticles have the
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potential to overcome drug penetration barriers and deliver clinically relevant anticancer
drugs.

Figure 3.4 Doxorubicin release in cylindroids. (a)–(c), Red fluorescence images and the
corresponding radial intensity profiles of cylindroids treated with positive DOX–AuNP
(a), negative DOX–AuNP (b), and free DOX (c). Dotted circles indicate cylindroid edges.
Scale bars, 200 mm. (d) and (e), Ratio of average fluorescence intensities in the outer
region to those in the inner region of the cylindroids, 30 h after treatment (d) and as a
function of time (e). Errors are standard error of the mean, and significance was
determined using Student’s t-test (*P < 0.05; n = 3).
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3.2.3 Diffusion of nanoparticles in matrix material
In addition to regulating cellular uptake, surface charge also significantly affects
the diffusivity of gold nanoparticles in the extracellular matrix. Diffusivity in the
extracellular matrix was modeled using a cell-free diffusion chamber, which confined
Matrigel between a trench cut in a polycarbonate block and the bottom surface of a well
plate (Figure 3.5a). In this model, diffusion occurred in only one direction: from the
exposed surface to the center of the trench. Concentrations of FITC and FITC–AuNP
were measured as a function of time and location by acquiring a series of fluorescence
images along the longitudinal direction every 2 h. Intensity gradients decreased from the
edge towards the centre of the Matrigel trench, and the slope of the gradients diminished
with time (Figure 3.5b and c). Diffusion coefficients were determined by nonlinear leastsquares fitting of the intensity gradients to a Fickian diffusion model (Figure 3.5c). The
diffusion coefficient for FITC was (42 ± 2) × 10-7 cm2 s-1, which was larger than both
gold nanoparticles by an order of magnitude (Figure 3.5d). Simulations with this
diffusion coefficient matched the concentration profiles seen in the cylindroids (Figure
3.3), suggesting that diffusion alone controlled the delivery of free FITC. Anionic gold
nanoparticles had a larger diffusion coefficient, (9.0 ± 0.1) × 10-7 cm2 s-1, than cationic
nanoparticles, (7.6 ± 0.1) × 10-7 cm2 s-1 (P < 0.005; n = 3; Figure 3.5d). The lower
diffusion coefficient of positive particles suggests that electrostatic interactions with
negatively charged macromolecules in the matrix slowed particle diffusion. The major
components of the extracellular matrix in tumors and spheroids are collagen and
proteoglycans. 39 , 40 , 41 Matrigel is derived from tumor matrix materials, 42 which are
negatively charged under physiological conditions. Because cationic and anionic particles
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have similar molecular weights and hydrodynamic radii, it is likely that electrostatic
interactions with the matrix are the primary cause of the difference between the diffusion
coefficients. Three mechanisms control the timing and location of drug delivery into
tumors using nanoparticles: diffusion, cellular uptake and ligand dissociation. Our results
indicate that, of the three, cellular uptake is the dominant mechanism. In all cylindroids,
fluorescence appeared early in their centers (Figure 3.3). If diffusion were the limiting
mechanism, fluorescence would first appear at the outside edge and progress into the
center. The measured diffusion coefficients in the matrix material (Figure 3.5d) confirm
that diffusion can account for the rapid appearance of particles in the cylindroid centers.

Figure 3.5 Effect of surface charge on diffusivity through extracellular matrix material.
(a) Schematic representation of loading module filled with Matrigel. (b) Green
fluorescence images acquired from the bottom of the loading module 4 and 24 h after
adding particles. Dotted lines at both ends indicate the Matrigel edges. Scale bar, 500
mm. (c) Fluorescence intensity profiles in Matrigel along the x-axis as a function of time
(symbols) and intensity profiles generated by fitting to a Fickian diffusion model (solid
lines). (d) Comparison of diffusion coefficients of FITC, cationic and anionic gold
nanoparticles in Matrigel (*P < 0.005; n = 3).
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3.2.4 Modeling diffusion and cellular uptake/release
A descriptive mathematical model was developed to interpret the coupled effects
of extracellular diffusion (Figure 3.1b) and cellular uptake/release (Figure 3.1d) on
molecular nanoparticle delivery. The model framework was designed to show how
dynamic nanoparticle measurements in cylindroids provide preliminary information
about nanoparticle behavior under physiological conditions. The model consisted of two
transient partial differential equations, one for gold nanoparticles, and the other for free
intracellular fluorophore. Concentration profiles for particles and released ligand were
predicted using in vitro calibrations of ligand release (Figure 3.2a). Based on confocal
microscopy results (Figure 3.3j), all ligand dissociation was modeled as an intracellular
reaction. Internalization of FITC–AuNPs and release of FITC–SH were modeled as a
single reaction with radially dependent forward (k1) and reverse (k2) rate constants
(Figure 3.1d). Nanoparticle diffusion coefficients were derived from measured
diffusivities in Matrigel (Figure 3.5). The modeling results fit the experimental data well,
and predict that positively charged particles will outperform negative particles for most,
but not all applications (Figure 3.6). The modeling results (solid lines in Figure 3.6a and
b) capture a number of key characteristics of the fluorescent patterns shown in Figure 3.3
and the experimental data points (symbols, Figure 3.6a and b). First, a higher
fluorescence was observed in the inner regions than in the outer at early time points.
Second, positive particles showed a monotonic increase in fluorescence, and this increase
was more pronounced in the outer regions. Third, negative particles displayed saturation
of fluorescence. By separating the fluorescence contributions from free and bound
fluorophore, the modeling results indicate that particle diffusion was rapid, and the
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appearance of free fluorophore by uptake and dissociation controlled overall fluorescence
(Figure 3.6c). Calculated kinetic rates suggest that viable cells had a higher net uptake of
positive particles because of a lower export rate (k2) in both inner and outer regions (P <
0.05; n = 3; Figure 3.6d). For negative particles, the forward rate constant was only larger
in the inner region (P < 0.05; n = 3; Figure 3.6d). Modeling predictions were based on a
hypothetical tumor for which the geometry was inverted: particles diffused from a blood
vessel (0 < r < 5 µm) into tumor tissue (r > 5 µm). Because of their greater diffusion
coefficient, negative particles penetrated deeper into the interstitium at all times (Figure
3.6e). However, the concentration of released intracellular ligand was greater for positive
particles, because of their larger net uptake rate (Figure 3.6f). This predicts that deep
penetration of negative particles may be mitigated by the elevated interstitial fluid
pressures often observed in tumors in vivo.43, 44, 45 For both particles, the concentration of
released ligand reached a maximum between 20 and 30 h (Figure 3.6f). Regions of
proliferating (10–70 µm) and quiescent (75–120 µm) cells were defined based on single
cell analysis performed in cylindroids. The average concentrations of released ligand for
positive particles in the proliferating and quiescent regions were more than 11-fold and 8fold greater at all times, respectively (Figure 3.6g). Deep in the tissue (> 1 mm) the
concentration of released ligand was greater for negative particles at later times (> 20 h;
Figure 3.6h). These results suggest that positive particles will release more ligand to most
cells at all times (Figure 3.6f and g) and therefore would be advantageous for most
applications. Complementarily, negative particles would have an advantage in delivering
drugs deep into tissue (Figure 5d and figure 6h) and would be useful for treating tumors
with large intervessel spacing and high hypoxic tolerance.
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Figure 3.6 Rate constants of cellular uptake and predictions of particle and ligand
distribution in tumors. (a) and (b) Fluorescence intensity profiles measured in
fluorescence images of cylindroids (symbols) and those predicted by the mathematical
model (solid lines). Concentrations were normalized by the maximum concentration of
FITC–AuNP in the cylindroids. (c) Independent concentration profiles of fluorophore
bound to nanoparticles (FITC–AuNP) and released fluorophore ligand (FITC–SH)
predicted by the computation model. (d) Comparison of forward (k1) and reverse (k2) rate
constants in different regions. Errors are standard error of the mean, and significance was
determined using Student’s t-test (*P < 0.05). (e) and (f) Modeled concentrations of
FITC–AuNPs and released FITC–SH as a function of distance from blood vessels of a
hypothetical tumor. Clearance half-life of FITC–AuNPs was assumed to be 3 h. (g)
Average concentrations of FITC–AuNPs in the regions 10–70 µm (proliferating) and 75–
120 µm (quiescent) from the blood vessel wall as a function of time. (h) Average
concentrations of released FITC in deep tumor regions (1.0–1.5 mm) as a function of
time.

3.3 Summary and future outlook
Using a combination of experimental in vitro tumor models and mathematical
modeling, we have shown that, under most circumstances, positively charged
nanoparticles improved delivery of payloads to the majority of cells in tumors, whereas
negatively charged particles would perform better when delivering drugs deep into
tissues. Positive particles had significantly higher uptake and dissociation by viable cells,
whereas negative particles diffused at a faster rate. Both positive and negative particles
penetrated tissues rapidly, and for both, the rate of cellular uptake and dissociation was
slower than extracellular diffusion. The mathematical models suggested that the rate of
cellular uptake of both particles was fast in apoptotic and necrotic tissues. Furthermore,
the uptake kinetics of positive particles is irreversible, but is reversible for negative
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particles over the timescales investigated. The ability to tune surface charge to control
tissue penetration and drug release makes gold nanoparticles a flexible and powerful drug
delivery vehicle.

3.4 Synthesis of materials and experimental methods
3.4.1 Synthesis of ligand and fabrication of nanoparticle

Figure 3.7 Synthetic procedure of the thioalkylate tetra (ethylene glycol) FITC and Dox
conjugated ligands (a) 1. methanesulfonyl chloride, TEA, DCM, RT, 4h, 2. sodium azide,
DMF, 4h. (b) triphenylphosphine, THF. (c) fluorescein isothiocyanate, acetone. (d) TFA,
TIPS, DCM, RT, 4h, (e) hydrazine, MeOH, reflux. (f) Doxorubicin, MeOH
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Synthesis of compound 2
Compound 2 Trityl protected thioalkyl tetra (ethylene glycol) alcohol 1 (5 g, 8.02
mmol)[2] was dissolved in dry dichloromethane (80 mL) that was placed in an ice bath.
When the temperature reached about 0 °C, triethylamine (1.67 mL, 12.03 mmol) and
methanesulfonyl chloride (1.25 mL, 16.04 mmol) were added successively. The mixture
was stirred at room temperature for 4 h. The reaction mixture was evaporated to yield the
crude product (5.72 g). The crude mesylated compound was then dissolved in dry
dimethyl formamide (30 mL). Subsequently, sodium azide powder (1.04 g, 16.04 mmol)
was added to the solution. The mixture was stirred at 80 oC for 4 h. After cooling to room
temperature, the solution was poured into 100 mL ice-water. The mixture solution was
extracted by CH2Cl2 (3 x 25 mL). The organic phases were combined and washed with
brine. The crude product was charged on a silica gel chromatographic column with ethyl
acetate as eluent for purification. Yields were around 88 %. 1H NMR (400 MHz, CDCl3,
TMS): δ 7.41 (m, 6H, HAr), 7.27 (m, 6H, HAr), 7.20 (m, 3H, HAr), 3.68 (m, 12H,
−OCH2−), 3.58 (m, 2H,−CH2O−), 3.44 (t, 3J = 6.8 Hz, 2H, −CH2O−), 3.37 (t, 3J = 5.0 Hz,
2H, −CH2O−), 2.13 (t, 3J = 7.4 Hz, 2H, −SCH2−), 1.57 (m, 2H, −CH2−), 1.38 (m, 2H,
−CH2−), 1.20 (m, 14H, −CH2−).

Synthesis of compound 3
A mixture of Trityl protected tetra (ethylene glycol) azide 2 (2.0 g, 3.08 mmol) and
triphenylphosphine (0.97 g, 3.69 mmol) were dissolved in tetrahydrofuran (20 mL). After
that, water (0.5 mL) was added to the solution mixture. The mixture was stirred at room
temperature for 12h. The mixture was poured into water. The aqueous suspension was
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extracted by dichloromethane (3 x 25 mL) and washed thoroughly with brine and dried
over anhydrous magnesium sulfate. After filtration, the combined organic phase was
evaporated to provide a white solid. The crude mixture was charged on silica gel column
with methanol:dichloromethane:ammonium hydroxide (50:45:5) as eluent for purification
to yield compound 3 (1.39 g, 73%) 1H NMR (400 MHz, CDCl3, TMS): δ 7.40 (m, 6H,
HAr), 7.27 (m, 6H, HAr), 7.17 (m, 3H, HAr), 3.66 (m, 10H, −OCH2−), 3.58 (m,
2H,−CH2O−), 3.50 (t, 3J = 5.16 Hz, 2H, −CH2O−), 3.44 (t, 3J = 6.68 Hz, 2H, −CH2O−),
2.12 (t, 3J = 7.3 Hz, 2H, −SCH2−), 1.56 (m, 2H, −CH2−), 1.38 (m, 2H, −CH2−), 1.22 (m,
14H, −CH2−). MS (ESI): m/z 622.5 [M++H] (calcd for 622.4).

Synthesis of compound 4 and 5
To a stirred solution of trityl protected tetra (ethylene glycol) amine 3 (1.0 g, 1.60 mmol)
in dry acetone (ca. 10 mL) was subsequently added Fluorescein isothiocyanate (FITC)
(0.543 g, 1.33 mmol). After stirred for 6 h at room temperature, the reaction mixture was
evaporated to remove acetone. The crude product 4 was then dissolved in dry
dichloromethane (ca.10 mL) and stoichiometric trifluoroacetic acid (2.5 mL) was added
under stirring. Subsequently, triisopropylsilane (0.65 mL, 3.20 mmol) was added. The
reaction was allowed to proceed at room temperature for 12 h. The solvent and excess
trifluoroacetic acid and triisopropylsilane were removed under reduced pressure. The
product 5 was confirmed by mass spectrometry without purification. MS (ESI): m/z
769.4 [M++H] (calculated for 769.3).
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Synthesis of compound 7
A mixture of hydrazine (1.37 g, 43 mmol) and compound 6 (1.0 g, 4.30 mmol) were
dissolved in methanol (5 mL). After stirring for 3h at 70 °C, the solvent was removed
under reduced pressure. The crude product was then poured into a mixture of
dichloromethane and distilled water. Organic layer was separated and concentrated at
reduced pressure to afford compound 7 as a white powder. (0.78 g, 78 %) 1H NMR (400
MHz, CDCl3, TMS): δ 6.98 (s, 1H, -NH-), 3.90 (s, 2H, -NH2), 2.50 (q, J = 7.2 Hz, 2H,
HS-CH2-), 2.50 (q, J = 7.3 Hz, 2H, -CH2-CO-), 1.55 (m, 2H, −CH2−), 1.25 (m, 14H,
−CH2−).

13

C NMR (100.64 MHz, CDCl3, TMS) δ 174.05, 34.57, 34.01, 29.42, 29.36,

29.25, 29.02, 28.33, 25.49, 24.65.

Synthesis of compound 7, Dox-SH
A methanol solution of compound 7 (0.03 g, 0.13 mmol) and doxorubicin (0.05 g, 0.08
mmol) was stirred overnight at 60 °C under argon. The reaction mixture was concentrated
and precipitated into hexane/ethyl acetate (1:2, v/v). The product was further purified by
washing with hexane and ethyl acetate to give compound 8 as a red solid. (0.04 g, 61 %)
The product was confirmed by mass spectrometry. MS (ESI): m/z 758.5 [M++H] (calcd
for 757.89).
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Synthesis of mixed monolayer-protected gold nanoparticles
Pentanethiol coated gold nanoparticles (2 nm in diameter) were synthesized according
to the method reported by You et. al.46 The synthetic procedure of the thioalkylate tetra
(ethylene glycol) fluorescein isothiocyanate (FITC) and doxorubicin (Dox) conjugated
ligands is represented in Scheme S1 and the details of each reaction step are as follows:

FITC-AuNP fabrication
The cationic and the anionic nanoparticles with FTIC conjugations were afforded by
adding 20 mg of 1-pentanethiol coated gold nanoparticles in dichloromethane into the
dichloromethane-methanol mixtures of 5mg thioalkylate tetra (ethylene glycol) FITC
conjugated ligands (FITC-SH) and 50 mg thiolalkyl tetra (ethylene glycol)lyated
trimethyl ammonium ligand (TTMA) or 50 mg thiolalkyl tetra (ethylene glycol)lyated
carboxylic acid ligand (TCOOH), respectively. The mixture were then stirred at room
temperature for 2~3 days. After all the solvents are evaporated, the ligand-exchanged
nanoparticles were washed thoroughly with hexanes, diethyl ether and dichloromethane
to remove all the free ligands and were collected by centrifugation. The nanoparticles
were dried under high vacuum. The absence of free ligands were confirmed by 1H-NMR.

Fluorescence calibration and loading ratios
Fluorescence intensities of p-FITC-AuNP, n-FITC-AuNP and FITC-SH were measured
at 0.5 and 1.0

M in DMEM by fluorimetry (SPECTRAmax GEMINI XS, Molecular
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Devices) to calibrate fluorescence intensity and determine the FITC-SH loading ratio.
The loading ratio is the number of conjugated FITC ligands per gold core. Conjugation to
the gold cores quenches FITC-SH fluorescence, and treatment with potassium cyanide
rapidly reacts with the gold cores and triggers FITC-SH release. Potassium cyanide, at a
final concentration of 20mM, was added to solutions of p-FITC-AuNP and n-FITCAuNP in DMEM. The solutions were incubated at 37 ºC for 4 hrs and fluorescence was
measured by exciting at 480nm and detecting at 520nm. The ratios of fluorescence
intensity to concentration were determined by linear regression and were subsequently
used to convert from intensity to concentration. Quenching effects were determined by
comparing the fluorescence intensity of the p-FITC-AuNP and n-FITC-AuNP solutions
with and without KCN. The loading ratio was determined by dividing the 6fluorescence
intensities of FITC ligands released from gold cores by free FITC-SH at the same
concentrations.

Dox-AuNP fabrication and characterization
To fabricate Dox-AuNP via ligand place exchange reaction, 10 mg of 1-pentanethiol
coated gold nanoparticles was mixed with 3 mg of Dox-SH and 27 mg of TTMA or
TCOOH ligands in a mixture of dichloromethane (5 mL) and methanol (5 ml). The
solution was stirred at room temperature for 24 hours. Solvent was removed by rotary
evaporator and nanoparticles were washed with hexane and diethyl ether (20 mL x 5).
Nanoparticles were further purified by dialysis in phosphate buffer (pH: 7.8) using
SnakeSkin pleated dialysis tubing (10,000 MWCO) for 2 days to remove all free ligands.
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The number of Dox-SH per particles was calculated as followings. Dox-AuNP (0.4

M)

was incubated at 37 °C for 24 h in buffer (pH: 2.0) solution. Dox on particle was released
as the hydrazone linkage was completely hydrolyzed at low pH. Dox is quenched by gold
nanoparticles and photoluminescence was only observed upon Dox release. Release of
Dox 7was monitored using fluorimetry (Figure 3.8a). The solution was centrifuged using
Amicon Ultra-4 tube (10,000 MWCO) to separate released Dox. Concentration of the
filtrate was calculated based on the Beer-Lambert law (max = 490 nm) using
spectrophotometry (Figure 3.8b). By comparing the absorbance of the filtrate with the
absorbance before incubation, the number of Dox-SH attached on a particle was
estimated to be 6 Dox-SH ligands per particle. The number of Dox-SH per n-Dox-AuNP
was calculated via potassium cyanide decomposition. A 1 ml solution of 4 μM n-DoxAuNP in THF was added to 1 mL of a 0.1 M aqueous KCN solution, followed by brief
agitation. After 2 hr, the plasmon absorption band of n-Dox-AuNP at 520 nm was
completely decayed, while absorbance of Dox-SH remained. The concentration of DoxSH was calculated based on the Beer-Lambert law (λ = 560 nm). A molar extinction
coefficient of Dox-SH in THF/H2O (1:1) was obtained for this estimation (ε = 9.69 x 103
at 560 nm). By comparing with the concentration of n-Dox-AuNP before etching, the
number of attached Dox-SH was estimated to be 5 ligands per particle.
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Figure 3.8 (a) The Dox-AuNP released Dox at pH 2 for 24 h incubation but remained
stable at pH 7.4. (b) Uv-spectrum of Dox-AuNP before incubation and a filtrate after
incubation.

3.4.2 Experimental methods
FITC–AuNP and DOX–AuNP uptake and ligand release in monolayer culture
LS174T human colon carcinoma cells were grown in DMEM (1 g l-1 glucose)
supplemented with 10% fetal bovine serum at 37 °C with 5% CO2 in a humidified
incubator. Cells in monolayer cultures were incubated with 1 mM FITC–AuNPs for 6 h,
and were washed with PBS three times before image acquisition. Confocal fluorescence
microscope images were acquired with a Zeiss LSM510 microscope equipped with a ×25
objective lens. A 488-nm argon laser was used for excitation, and emission was acquired
at 505 nm (long pass).

FITC–AuNPs and DOX–AuNPs in cylindroids
Cylindroids were prepared from spheroids as described previously and in the
Supplementary Information. After equilibration, cylindroids were treated with 125 mM
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FITC, 1 mM FITC–AuNP, 1 mM DOX, or 1 mM DOX–AuNP. Transmitted and
fluorescence images were acquired with an Olympus IX71 microscope with a ×10
objective at 0, 11, 21, 38, 46 h after treatment. Radial fluorescence intensity profiles in
the cylindroids were generated using a customized script in ImageJ (NIH Research
Services Branch). Average fluorescence intensities were determined for two annular
regions: 175–200 mm from the centre (inner) and 25–50 mm from the periphery (outer).
For confocal fluorescence microscopy, cylindroids were prepared in 35-mm glassbottomed culture dishes. Images were acquired with a Zeiss LSM510 microscope
equipped with a × 63 oil-immersion objective. A 488-nm argon laser was used for
excitation, and emission was acquired at 505 nm.

Thiol compounds in cylindroids
The distribution of GSH was determined by measuring the fluorescence intensity of
OPA derivatives. OPA reacts with amino acids in the presence of thiol compounds to
form fluorescent derivatives. Cylindroids were incubated with 250 ml of 100 mM OPA in
PBS. Transmitted and fluorescence images were acquired 4, 18 and 36 h after treatment.
Samples were excited at 350 nm and measured at 460 nm.

Extracellular diffusion of FITC–AuNP
Diffusion of gold nanoparticles was measured in Matrigel in a loading module (Figure
3.5a) as described in the Supplementary Information. The loading module was prepared
by making a channel (3.1 × 0.5 × 6.2 mm3; W × H × L) in the top of a polycarbonate
block (9.6 × 4.8 × 6.2 mm3). Before loading, the well plate was plasma-treated for 5 min
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and sterilized with UV for 4 h. The module was loaded with 12 ml Matrigel, which was
allowed to gelate at 37 °C for 5 min. Pre-warmed DMEM (2.0 ml) was added to each
well and, after 2 h, was replaced with DMEM containing 1 mMFITC–AuNP. Transmitted
and green fluorescence images were acquired every 2 h for 36 h. Spatial concentration
profiles were obtained by averaging pixel values across the width of the channel.
Diffusion coefficients of FITC, p-FITC–AuNP and n-FITC–AuNP were determined by
fitting measured fluorescence intensities to a mathematical diffusion model. Numerical
solutions were calculated using finite elements, and best-fit diffusion coefficients were
determined by nonlinear least-squares optimization in Matlab (MathWorks).

Mathematical modelling of particle diffusion and cellular uptake in cylindroids
Internalization

of

gold

nanoparticles

from

the

extracellular

space

and

glutathionemediated replacement were represented with a one-step reversible reaction:

where k1 and k2 are forward and reverse reaction constants. Coupled conservation
equations for FITC–AuNPs and released FITC–SH incorporated expressions for
extracellular nanoparticle diffusion and the kinetics of particle uptake and ligand release:
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From confocal measurements, the cell volume fraction fv was found to be 0.48. The
effective nanoparticle diffusion coefficients Deff were derived from the Matrigel
experiments. Reaction rates were assumed to be functions of position as described in the
Supplementary Information. Thismodel was solved using finite elements and fit to
measured fluorescence concentrations by nonlinear least-squares optimization in Matlab.
Calculated fluorescence values were determined from the sum of the volumefractionweighted particle (FITC–AuNP) and released ligand (FITC–SH) concentrations.
Calculated rate constants were reported as average values inside the inflection point, r,Rt
(inner) and between the inflection point and the edge, Rt < r < 1 (outer). Significance was
determined using unpaired Student’s t-tests with unequal variance. Particle diffusion and
ligand release was modelled in a hypothetical tumor as described in the Supplementary
Information. In thismodel, the blood was assumed to be well mixed, and particles were
cleared with a 3-h half-life

Nanoparticle uptake into viable and dead cells in monolayer cultures
To measure the effects of cell viability on uptake, cells were treated with HEPES
buffered medium (viable cells) or saline (dead cells), both containing 500 nM positive
Dox-AuNP or 500 nM negative Dox-AuNP. Viability was confirmed using 800 nM
Ethidium Homodimer (Eth-D1; Invitrogen, Carlsbad, CA). Samples were excited using a
546/10 nm filter and measured through a 590 nm long pass emission filter (Chroma,
Rockingham, VT). The increase in fluorescence intensities from 1 hour to 17 hours post
treatment was evaluated at nine 8locations for each treatment. Values were normalized by
the average increase in intensity of viable cells. Particle uptake was dependent on cell
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viability (Figure 3.9). Following growth in medium or saline, cells were either viable or
dead as confirmed by staining with ethidium homodimer, Eth-D1 (Figure 3.9). Both
positive and negative particles were taken up viable cells, but uptake was significantly
greater in necrotic cells. Non-viable cells have greater uptake because they have lost
membrane integrity.

Figure 3.9 Nanoparticle uptake into viable and dead cells a, b, Transmitted and red
fluorescent images of viable (a) and dead (b) cells in monolayer culture treated with
positive Dox-AuNP. c, Normalized fluorescence intensities of viable and dead cells
following uptake of viability stain Eth-D1, positive Dox-AuNP and negative Dox-AuNP.
Error bars are standard error of the mean (*P < 0.05, n=9). Scale bars are 50µm.
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Cylindroid preparation
Cylindroids were formed from spheroids as described previously.5 To grow spheroids, a
single-cell suspension was inoculated into cell culture flasks coated with poly(2hydroxyethyl methacrylate). After 6-8 days, cylindroids were prepared by placing
spheroids in the 150 ± 15μm gap between the bottom of 48 well plates and 3mm diameter
cylindrical plugs projecting from the cover. Fresh media (200 µl) was added to each well
and cylindroids were allowed to equilibrate overnight.

Image acquisition
Cylindroid images were acquired with an Olympus IX71 microscope with a 10X
fluorescence objective. FITC and Dox samples were excited at 470 and 546 nm and
measured at 525 and 590 nm, respectively. Careful attention was made during image
acquisition to ensure that quantitative comparison was possible, including 1) maintaining
a constant exposure time for all image acquisitions and 2) acquiring a background image
for all cylindroids before the addition of treatment or fluorophore. Background
fluorescence was subtracted before analysis. To cover the large size of cylindroids, 4 (2 
2) or 9 (33) individual images were acquired and tiled using a script in IPLab (BD
Bioscience).

Radial fluorescence intensity profiles
Radial fluorescence intensity profiles in cylindroids were generated using a customized
script in ImageJ (NIH Research Services Branch). Cylindroid radii were determined from
transmitted light images. Average radial intensities were obtained by summing the
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intensities of all pixels at a given radius and dividing by the number of pixels. Distances
were normalized by the cylindroid radius and fluorescence intensities were normalized by
the maximum fluorescence intensity. Background autofluorescence was corrected by
subtracting the intensity profile of the fluorescence image at 0 hrs. Average temporal
behavior was determined for the four time points by averaging all pixels in two annular
regions: an inner region (175 - 200 μm from the center) and an outer region (25 - 50 μm
from the periphery).

Extracellular diffusion of FITC-AuNP
Diffusion of gold nanoparticles was measured in Matrigel in a loading module attached
to the center of a well plate (Figure 3.5a). The loading module was prepared by making a
channel (3.1 x 0.5 x 6.2 mm; W x H x L) in the top of a polycarbonate block (9.6 x 4.8 x
6.2 mm). Before loading, the well plate was cleaned by plasma treatment for 5 min and
sterilized with UV for 4hrs. Matrigel was kept at 4 ºC to prevent gelation. After loading,
12

l added Matrigel was allowed to gelate at 37 °C for 5min. Pre-warmed DMEM

(2.0ml) was added to each well. After 2hrs, the medium was replaced with fresh DMEM
containing 1μM FITC-AuNPs. Transmitted and green fluorescence images (excitation:
470/40nm, emission 525/50nm) were acquired every 2 hrs for 36 hrs using a 4X
UPlanApo objective. To cover the large area of the module, four images were acquired
and tiled using IPLab. Background autofluorescence was corrected by subtracting the
fluorescence image taken at 0hrs from all fluorescence images.
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Mathematical modeling of diffusion in Matrigel
Diffusion coefficients of FITC, p-FITC-AuNP and n-FITC-AuNP in Matrigel were
determined by fitting measured fluorescence intensities as a function of time and location
in the loading module (Figure 3.5a) to a mathematical model of diffusion

with the following initial and boundary conditions

where C is nanoparticle concentration, L is length in the x-axis direction, and f1(t) and f2(t)
are the measured concentrations at the boundaries as functions of time. Gradients of
diffusing components in y- and z-axis were assumed to be negligible compared to the
gradient along the x-axis (Figure 3.5a). The model assumes that the initial concentrations
in the matrix were zero. Particle concentrations were determined from fluorescence
intensities using the calibration described above. Particle concentration profiles as a
function of distance from the edge (x-axis) were obtained by averaging pixel values
across the width (y-axis). Numerical solutions were calculated using finite elements and
diffusion coefficients were determined by nonlinear least square optimization using
Matlab (The MathWorks).
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Mathematical modeling of diffusion and reaction in cylindroids
A mathematical model was constructed to couple particle diffusion and cellular uptake.
Effective diffusivities were derived from measured diffusivities in Matrigel, and were
proportional to the volume of extracellular space, 1 - fv, and inversely proportional to the
tortuosity, which was assumed to have a value of 2.7. Internalization of gold
nanoparticles from extracellular space and glutathione-mediated replacement were
represented with a one-step reversible reaction. A reversible reaction was used to model
cellular uptake and release, because it was the most likely cause of the saturation kinetics
observed with negative particles. Reaction rates were assumed to be first order with
respect to FITC-AuNPs and released FITC-SH. Released FITC-SH was assumed to not
diffuse in the extracellular space. Initially neither species was assumed to be present
throughout the cylindroid, and the symmetric boundary condition was assumed at the
center. At the interface between the cylindroids and the culture media the measured
particle concentrations were used as boundary conditions.

Reaction rates as functions of position
Reaction rates were assumed to be functions of position and were modeled with a
sigmoidal function that asymptotically approaches maximum and minimum values with a
smooth transition.

The subscript j indicates the direction of the reaction (forward, 1 or backward, 2); kjmin
and kjmax are the minimum and maximum reaction rates; Rt is the location of the inflection;
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and  is the width of the transition (Figure 3.11). This equation asymptotically
approaches kjmin and kjmax as the normalized radius, r, approaches 0 and 1, respectively
(Figure 3.11). In figure 3.11 Rt = 0.6 and σ = 0.1. With these parameters, k is within 10-6
of kmax at r = 0 and 10-4 of kmin at r = 1. Additionally, k is at 10% of the maximum and
minimum values at r = 0.45 and r = 0.75. Nonlinear least square optimization determined
kjmin, kjmax and Rt by minimizing the error between measured and calculated radial
concentration profiles. The width of transition () was fixed at 60

m based on the

fluorescence images (Figure 3.3), which was less than 10% of the radius of most
cylindroids. The location of the inflection, Rt, was found to be between 0.6 and 0.8 for all
cylindroids. All parameters were determined for the forward and reverse reactions of both
particle types.

Figure 3.10 Profile of the reaction constant as a function of the radial distance from the
center of the cylindroid. The values kmin and kmax are the maximum and minimum value of
the sigmoidal function; Rt is the location of the inflection; and  is the width of the
transition.
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Modeling particle diffusion and ligand released in a hypothetical tumor
Particle and released ligand concentrations were predicted using the calculated
diffusion and reaction kinetic parameters. To more closely describe tumor biology, the
cylindrical geometry was inverted; diffusion was assumed to originate from the lumen of
a 10 μm blood vessel. The concentration of particles in the blood was assumed to be well
mixed and be cleared by simple two-compartment, monotonically decreasing
pharmacokinetics. Previous measurements in mice estimated that the clearance half-life
of PEG-coated gold nanoparticles is approximately three hours. The average released
ligand concentration was determined in three regions as a function of time, 10-70, 75-120,
and 1000-1500μm.
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CHAPTER 4

RECOGNITION-MEDIATED ACTIVATION OF THERAPEUTIC GOLD
NANOPARTICLES INSIDE LIVING CELLS

4.1 Introduction
Supramolecular chemistry provides a versatile tool for the organization of
molecular systems into functional structures and the actuation of these assemblies for a
myriad of applications through the reversible association between complementary
components. Supramolecular chemistry uses non-covalent interactions to provide
controlled assembly of molecular building blocks. 1, 2, 3, 4, 5, 6 By virtue of reversible noncovalent interactions (e.g. hydrogen bonding, ion-ion, pi-pi stacking and van der Waals
interactions), supramolecular complexes are inherently dynamic in nature and highly
selective toward other complementary guest molecules through these various weak and
reversible interactions.

7

As a result of the modularity and the reversibility,

supramolecular systems can be engineered to assemble and disassemble spontaneously in
response to a range of triggers. 8
The versatility of supramolecular chemistry makes this strategy a promising tool
for biomedical science. A number of host-guest supramolecular systems (e.g. nanovalves
and artificial molecular machines) have been reported for the delivery of drugs and other
therapeutic materials.

9 , 10 , 11

The engineering of such systems has been achieved

principally through the design of molecular recognition partners, thereby fine tuning the
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molecular recognition event to meet the demands of specific applications. A number of
synthetic receptors including cucurbit[n]uril (CB[n]),12 cyclodextrins,13, 14 cyclophanes,15
calixarenes, 16 and crown ethers 17 , 18 have been used for this purpose. Of these host
systems, the cucurbit[n]uril (CB[n]) family of macrocyclic receptors is particularly useful
due to their well defined structure and recognition properties coupled with their ability to
form stable host-guest inclusion complexes with a wide variety of guest molecules in
aqueous media. 19, 20, 21 This capability has been exploited for the creation of delivery
vectors, including the encapsulation of platinum drugs inside the cavity of CB[7] to
increase the stability of the drugs in biological environments. 22 , 23 , 24 , 25 In another
example, the strong affinity of spermine towards CB[n] has been utilized to tailor a DNA
delivery vector for enhanced transfection efficiency and target specificity.26, 27 In these
systems, the properties of the guest molecule have been modified as a result of the
supramolecular complexation with the host molecules, enhancing delivery properties.
In addition to modification of molecular properties, supramolecular chemistry
provides the capability of actuation.28, 29 Engineering of host-guest systems to function
inside the cell provides a potentially powerful strategy for the regulation of therapeutics.
We present here a supramolecular system featuring complementary diaminohexaneterminated gold nanoparticles (AuNP-NH2) and cucurbit[7]uril (CB[7]) that form a nontoxic assembly that is readily taken up by the cells (Figure 4.1). This host-guest complex
can be disassembled intracellularly by the orthogonal guest molecule 1-adamantylamine
(ADA) that features a very high affinity to CB[7]. Intracellular removal of CB[7] from
the nanoparticle surface results in a endosomal escape by the AuNP-NH2, thereby
activating the cytotoxicity of AuNP-NH2 and hence inducing cell death (Figure 4.1). This
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result presents a new strategy for triggering therapeutic systems through the use of
competitive interactions of orthogonally presented guest molecules, with immediate
advantages in dosage control and potential utility for dual-targeting therapies. This work
has been published as an article in the Nature Chemistry journal. 30

Figure 4.1 Structure of gold nanoparticle and use of intracellular host-guest
complexation to trigger nanoparticle cytotoxicity. (a) Structure of diaminohexaneterminated gold nanoparticle (AuNP-NH2) and cucurbit[7]uril (CB[7]). (b) Activation of
AuNP-NH2-CB[7] cytotoxicity by dethreading of CB[7] from the nanoparticle surface by
ADA.
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4.2 Results and discussion
4.2.1 Complexation/decomplexation between AuNP-NH2 and CB[7]
The therapeutic component of the system is provided by AuNP-NH2 (2.5 ± 0.4
nm core size) featuring a self-assembled monolayer of diaminohexane terminated thiol
ligands (Figure 4.1a). 31 The terminal diaminohexane moiety both renders the particle
cytotoxic (vide infra) and serves as a recognition unit for the formation of host-guest
inclusion complex with CB[7]. The association constant of this diamine-CB[7]
complexation process is ~ 108 M-1 and the complex has been shown to be stable under
biological conditions.

32

The complexation between AuNP-NH2 and CB[7] was

investigated using NMR titration experiments as shown in Figure 4.2. As the ratio of
CB[7]/ AuNP-NH2 increases, the peaks for the methylene groups of AuNP-NH2-CB[7]
are shifted upfield relative to those of AuNP-NH2. This behavior indicates that terminal
diaminohexane units were encapsulated inside the shielding zone of CB[7] cavity as
AuNP-NH2-CB[7] complex forms.33 At the ratio of 1:40 (AuNP-NH2:CB[7]), the signal
shift of the methylene groups was completely saturated, revealing the number of CB[7]
around a single nanoparticle is ~40. According to the thermogravimetric analysis (TGA),
the number of diaminohexane-terminated ligands on a single nanoparticle estimated is
~43 (Figure 4.2b), indicating almost complete encapsulation of diaminohexane units by
CB[7].
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Figure 4.2 (a) NMR titration between AuNP-NH2 and CB[7]. The resonance signals for
the methylene groups and) of AuNP-NH2-CB[7] were shifted upfield, relatively to
those in AuNP-NH2. (b) Thermogravimetric analysis (TGA) data of AuNP-NH2. The
average number of diaminohexane-terminated thiol ligand in a single nanoparticle
estimated is ~43.
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The AuNP-NH2-CB[7] complex was further characterized through transmission
electron microscopy (TEM) as shown in Figure 4.3. TEM images taken after uranyl
acetate staining showed that each gold nanoparticle was encapsulated by CB[7]. The
average overall diameter of the nanoparticles calculated from the TEM image of AuNPNH2-CB[7] is 11.4 ± 0.8 nm, which is in good agreement with the hydrodynamic
diameter observed by DLS experiment (12.1 ± 0.8 nm). In addition, no size change or
aggregation of nanoparticles was observed from UV-Vis spectra of the nanoparticles,
indicating no morphological change after complexation (Figure 4.4).

Figure 4.3 TEM image of AuNP-NH2-CB[7] complex after uranyl acetate staining.
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Figure 4.4 (a) UV-Vis spectra of nanoparticles. 0.6 µM nanoparticles were used to
measure the absorption spectra. No change in UV-Vis absorption band was observed
during complexation/decomplexaion process. TEM images of (b) AuNP-NH2, (c) AuNPNH2-CB[7], and (d) AuNP-NH2-CB[7] + ADA. No size change or aggregation of
nanoparticles was observed from TEM images, indicating no morphological change
during complexation/decomplexation process. TEM samples of AuNP-NH2, AuNP-NH2CB[7], and AuNP-NH2-CB[7] unsheathed by ADA were prepared by placing one drop of
the desired solution (3 μM) on to a 300-mesh Cu grid coated with carbon film. These
samples were analyzed and photographed using the same instrument without staining.
The average diameter of Au core is 2.5 ± 0.4 nm.

The competitive unsheathing of the AuNP-NH2-CB[7] complex by ADA
(commonly used as an antiviral or anti-Parkinsonian drug 34, 35, 36) was confirmed using
NMR and matrix-assisted laser desorption/ionization mass spectroscopy (MALDI-MS).
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Addition of ADA triggered the release of CB[7] from nanoparticles through creation of
the more favorable 1:1 ADA-CB[7] complexes (Ka = 1.7 x 1012). As expected, the shifted
resonance signals of the methylene groups of the ligands induced by complexation with
CB[7] were fully recovered as soon as ADA was added (Figure 4.5a). In MALDI-MS,
the AuNP-NH2 and AuNP-NH2-CB[7] exhibit characteristic ion peaks at m/z 479.44 and
1641.8 respectively, corresponding to the molecular ion (M+) of [HS-NH2] and [HS-NH2CB[7]]. After addition of ADA, the ion peak of [HS-NH2-CB[7]] disappeared and a new
peak of [ADA-CB[7]] appeared, indicating efficient complexation/decomplxation process
(Figure 4.5b).
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Figure 4.5 (a) Competitive behavior of host-guest binding equilibrium on nanoparticle
was demonstrated by NMR data. The shifted resonance signals of the methylene groups
of the surface ligands induced by complexation with CB[7] were fully recovered as soon
as ADA was added to the complex (AuNP-NH2-CB[7]) solution. (b) Matrix-assisted laser
desorption/ionization mass spectroscopy (MALDI-MS) spectrum. (I) AuNP-NH2, (II)
AuNP-NH2-CB[7], and (III) AuNP-NH2-CB[7] + ADA
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4.2.2 Cellular uptake, cytotoxicity and intracellular localization of the nanoparticles
The cellular uptake of the nanoparticles was quantified using inductively coupled
plasma mass spectrometry (ICP-MS). ICP-MS analysis revealed that the total amount of
the nanoparticles taken up by the cells was nearly identical for AuNP-NH2 and AuNPNH2-CB[7] (Figure 4.6). TEM analysis of the cells was employed to evaluate the impact
of CB[7] complexation on the intracellular fate/localization of the nanoparticles. As
shown in Figure 4.7, after 3 h incubation, both AuNP-NH2 and AuNP-NH2-CB[7] are
trapped within vesicular structures morphologically consistent with endosomes. This
observation is consistent with the behavior observed with other cationic nanoparticles, as
reported in our previous work. 37 , 38 After 24 h of incubation, however, AuNP-NH2
particles had escaped from the endosome and were dispersed in the cytosol (Figure 4.8).
In contrast, AuNP-NH2-CB[7] particles remained sequestered in the endosome with no
free particles observed in the cytosol (Figure 4.8) after the same period. Significantly,
incubation of AuNP-NH2-CB[7]-treated cells with ADA for 24 h resulted in the escape of
a substantial number of

particles into the cytosol (Figure 4.8c), consistent with

intracellular transformation of AuNP-NH2-CB[7] to AuNP-NH2 via dethreading.
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Figure 4.6 Cellular uptake of the gold nanoparticles. Quantification of the amount of
gold present in cells. Samples were analyzed by ICP-MS to determine the amount of gold
in MCF-7 cell after 3 h incubation with 0.5

M of AuNP-NH2 and AuNP-NH2-CB[7].

Both particles showed almost same cellular uptake. Cellular uptake experiments with
each gold nanoparticle were repeated 3 times, and each replicate was measured 5 times
by ICP-MS. Error bars represent the standard deviations of these measurements.

Figure 4.7 TEM images of cross sectional MCF-7 cells incubated for 3h with 0.5 µM (a)
AuNP-NH2 and (b) AuNP-NH2-CB[7].

Both particles were similarly trapped in

organelles such as endosomes.
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Figure 4.8 Intracellular localization of the gold nanoparticles. TEM images of cross
sectional MCF-7 cells incubated for 24 h with 2 µM (a) AuNP-NH2 and (b) AuNP-NH2CB[7]. Significant amount of AuNP-NH2 is present in the cytosol, however most of the
AuNP-NH2-CB[7] seems to be trapped in organelles such as endosome. (c) TEM images
of cross sectional MCF-7 cells incubated for 3 h with 2 µM of AuNP-NH2-CB[7] and
then further incubation with ADA for 24 h. In the intracellular environment ADA
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transforms AuNP-NH2-CB[7] to AuNP-NH2, which then escaped from the endosome and
observed to be dispersed in the cytosol. i, ii and iii are the magnified sections of part (c).

4.2.3 Activating therapeutic efficacy by ADA
Polyamine functionalized macromolecules 39 , 40 , 41 and nanoparticles 42 , 43 , 44 , 45
interact strongly with cell membranes and subcellular compartments, resulting in
membrane disruption and cytotoxicity. Complexation of AuNP-NH2 with CB[7] should
attenuate the positive charge of the particle surfaces, reducing the ability of the particles
to disrupt membranes (including the endosomal) and hence lower toxicity. The
cytotoxicity of AuNP-NH2 and AuNP-NH2-CB[7] was investigated in the human breast
cancer MCF-7 cell line using an Alamar blue assay. The AuNP-NH2-CB[7] complex was
substantially less toxic as compared to AuNP-NH2. After 24 h incubation, AuNP-NH2
exhibited cytotoxicity with an IC50 value of 1.3 µM (Figure 4.9). On the other hand,
AuNP-NH2-CB[7] complex did not inhibit cell proliferation at concentrations ≤ 50 µM
under the same experimental conditions, presumably arising from sequestration of the
particle in the endosome. Significantly, when the free thiol ligand was added to the cells
at concentrations consistent with those used in the study (80 µM, corresponding to the
same per-ligand concentration as 2 µM nanoparticle) toxicity was observed with both
threaded and unthreaded ligand, demonstrating the modulation of ligand toxicity on the
particle.
Given the observed intracellular dethreading of AuNP-NH2-CB[7] with ADA and
concomitant release from the endosome, the endosomal escape of the nanoparticles after
ADA treatment raises the possibility that toxicity of the AuNP-NH2-CB[7] complex can
be triggered by ADA. To test this hypothesis MCF-7 cells were incubated with 2 M of
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AuNP-NH2-CB[7] in culture medium for 3h, to allow endocytosis of nanoparticles. 46
Cells were then washed three times with PBS buffer, and then ADA was added to the
culture medium. Cells were then incubated for an additional 24 h. Cells treated with
AuNP-NH2 and AuNP-NH2-CB[7] alone exhibited 34 % and 100 % cell viability after 24
h incubation, respectively (Figure 4.9b). Treatment with 0.4 mM ADA led to 40 % cell
viability, approaching the level of lethality observed for the AuNP-NH2 control. The
result indicates that ADA acts as an effective trigger for the competitive release of CB[7]
from particles within the cell, with attendant activation of cytotoxicity.

Figure 4.9 Cytotoxicity of AuNP-NH2 and AuNP-NH2-CB[7] and modulating
cytotoxicity of the gold nanoparticles. (a) Cytotoxicity of AuNP-NH2 and AuNP-NH2CB[7] measured by Alamar blue assay after 24 h incubation in MCF-7. IC50 of AuNPNH2 was 1.3 µM and no cytotoxicity of AuNP-NH2-CB[7] was observed up to 50 µM.
(b) Triggering cytotoxicity using ADA. After 3h incubation of AuNP-NH2-CB[7] (2 µM)
in MCF-7 cell, different concentrations (0, 0.2 and 0.4 mM) of ADA in medium added
and further incubated at 37 ºC for 24 h. The cell viability was then determined by using
an Alamar blue assay. As controls, cell viability of AuNP-NH2 and AuNP-NH2-CB[7]
was measured after 24 h incubation (34 % and 100 %, respectively). Cell viability
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experiments were performed as triplicate and the error bars represent the standard
deviations of these measurements.

4.3 Summary and future outlook
In summary, we have demonstrated the use of synthetic host-guest chemistry to
provide triggered activation of a therapeutic system via competitive complexation. This
approach provides a potential strategy for the construction of synthetic host-guest
supramolecular systems capable of complex and sophisticated behavior within living
cells. Triggering therapeutic systems through the use of competitive interactions of
orthogonally presented guest molecules can be potentially useful for dual-targeting
therapies, i.e. targeting of both host and guest component. This provides the potential for
orthogonal (“effector/trigger”) drug delivery and therapeutic activation47, 48 that would be
capable of achieving higher levels of site specific activity, and reduced amounts of
collateral damage. Currently, we are exploring this strategy in vivo and thoroughly
considering issues (e.g. the practical use of ADA) related to the real-world application of
this system.
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4.4 Synthesis of materials and experimental methods
General
All the chemicals were purchased from Sigma-Aldrich or Fischer Scientific, unless
otherwise specified. The chemicals were used as received. Dichloromethane (DCM) used
as a solvent for chemical synthesis was dried according to standard procedure. The yields
of the compounds reported here refer to the yields of spectroscopically pure compounds
after purification. 1H NMR spectra of the nanoparticles and the complexes were recorded
on a Bruker AVANCE 400 at 400 MHz. MALDI-MS analyses were performed using a
Bruker Omniflex time-of-flight mass spectrometer. UV-Vis spectra were recorded on
Hewlett-Packard 8452A spectrophotometer. Dynamic light scattering (DLS) was
measured by Zetasizer Nano ZS.

4.4.1 Synthesis of ligand and fabrication of nanoparticle

Figure 4.10 Synthetic scheme for the preparation of diaminohexane-terminated ligand.
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Synthesis of compound 1
The trityl-protected thiol ligand (Trt-C11-TEG-OMs) was prepared according to our
previously reported procedure. 49 Trt-C11-TEG-OMs (0.150 g, 0.214 mmol) was first
dissolved in 2 mL of DCM: MeOH (1:1 v/v) mixture. The solution was then placed in a
20 mL glass vial and N-Boc-1,6-hexanediamine (0.479 mL, 2.143 mmol) was added to it.
The reaction mixture was heated to 50°C and stirred for ~48 h. The reaction mixture was
concentrated under reduced pressure and the residue was directly charged on a SiO2
column for purification (eluent: a gradient eluent of 0-10% methanol in DCM v/v). Yield
0.100 g (0.122 mmol, 57%, viscous pale yellow color liquid). 1H NMR (400MHz,
CDCl3): 7.40 (m, 6H, TrtHAr), 7.27 (m, 6H, TrtHAr), 7.20 (m, 3H, TrtHAr), 4.59 (br, 1H,
NHCO), 3.88 (t, 3J = 4.64 Hz, 2H, OCH2), 3.68-3.57 (m, 12H, CH2O +
OCH2), 3.44 (t, 3J = 7.02 Hz, 2H, CH2O), 3.11-3.06 (m, 4H, CH2NCO +
CCH2N), 2.90 (t, 3J = 8 Hz, 2H, NCH2C), 2.12 (t, 3J = 7.32 Hz, 2H, SCH2), 1.83
(m, 2H, CH2), 1.59-1.14 (m, 33H, CH2 + C(CH3)3). MS (ESI-MS) calculated for
C49H76N2O6S 820.5, found 821.8 [M+H]+.

Synthesis of diainohexane-terminated thiol ligand
The protected thiol ligand (compound 1, 0.300 g, 0.365 mmol) was dissolved in dry
DCM. The solution was purged with argon and an excess of trifluoro acetic acid (TFA,
0.600 mL) was added. During the addition period of TFA the color of the solution was
turned to yellow. Subsequently, triisopropylsilane (TIPS, 0.250 mL) was added to the
reaction mixture and the color of mixture slowly recovered to colorless. The reaction
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mixture was allowed to stir at room temperature for 6 h under argon atmosphere. The
volatile components (solvent, TFA and TIPS) were then distilled off under reduced
pressure. The pale yellow residue was purified by washing with hexane (15 mL × 3) and
diethyl ether (15 mL × 3). After drying under high vacuum a viscous colorless liquid was
obtained. Yield 0.175 g (0.248 mmol, 68%). 1H NMR (400MHz, CDCl3): 3.77 (brt, 3J =
4.14 Hz, 2H, OCH2), 3.64-3.57 (m, 12H, CH2O + OCH2), 3.44 (t, 3J = 6.94 Hz,
2H, CH2O), 3.18 (br, 2H, CCH2N), 2.99 (m, 4H, CH2N + NCH2C), 2.51 (q, 4J
= 7.38 Hz, 2H, SCH2), 1.78-1.26 (m, 26H, CH2).

Figure 4.11 Construction of diaminohexane-terminated gold nanoparticle (AuNP-NH2)
through place exchange reaction.

Procedure for construction of diaminohexane-terminated gold nanoparticle (AuNPNH2)
Gold nanoparticle (AuNP-NH2) was prepared through place-exchange reaction of 1pentanethiol protected gold nanoparticle (Au-C5). Au-C5 was prepared by following the
procedure reported by Brust et al.50As shown in Figure 5.11, nanoparticle was decorated
with diaminohexane-terminated thiol ligand by following the general procedure reported
by Murray et al. In a typical reaction, 0.015 g of Au-C5 was first dissolved in 1 mL of dry

122

DCM. Then, 0.038 g of diaminohexane-terminated thiol ligand dissolved in 5 ml
DCM:MeOH (4:1 v/v) was added carefully to the solution of Au-C5. The reaction
mixture was allowed to stir at room temperature for ~ 24 h. After ~ 24 h, argon was
bubbled through the nanoparticle solution to evaporate the solvents. The dark black color
nanoparticle residue was then washed with DCM (10 mL × 3) and 5% MeOH in DCM
v/v (10 mL × 2). After washing the nanoparticle was immediately dissolved in MiliQ
water and was allowed to stay at room temperature for ~12 h to remove the volatile
components. The aqueous solution of the nanoparticle was further purified and
concentrated by using molecular cut off filter (Amicon Ultra-4 tube, 10000 MWCO). The
filtrate was discarded and the trapped nanoparticle residue (on the cut off filter) was then
dissolved in D2O.

1

H NMR spectra in D2O was then recorded in a 400 MHz Bruker

machine. The nanoparticle was stable in solution for months and was stored in MiliQ
water at 4 °C.
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Figure 4.12 400 MHz 1H NMR spectrum of AuNP-NH2 in D2O. Inset shows the 1H
NMR spectrum of the diaminohexane-terminated thiol ligand in CDCl3.

4.4.2 Experimental methods
Cell Culture Experiment
MCF-7 cells were grown in a cell culture flask using low glucose Dulbecco's Modified
Eagle Medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified
atmosphere of 5% CO2. For cytotoxicity tests involving AuNP-NH2 and AuNP-NH2CB[7], MCF-7 cells were seeded at 20,000 cells in 0.2 ml per well in 96-well plates 24 h
prior to the experiment. During experiment old media was replaced by different
concentrations of AuNP-NH2 and AuNP-NH2-CB[7] in serum containing media and the
cells were incubated for 24 h at 37°C in a humidified atmosphere of 5 % CO2. The cells
were then completely washed with PBS buffer for three times and 10% Alarmar blue in
serum containing media was added to each well and further incubated at 37 °C for 4 h.
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The cell viability was then determined by measuring the fluorescence intensity at 570 nm
using a SpectraMax M5 microplate spectrophotometer. Curves were fitted by DoseRep
function in Origin 8. For measuring cytotoxicity of AuNP-NH2-CB[7] upon adding ADA,
MCF-7 cells were seeded at 20,000 cells per well in 96-well plate 24 h prior to the
experiment. The old medium was replaced by 2 M of AuNP-NH2-CB[7] in medium
containing serum and incubated for 3h. The cells were then completely washed with PBS
buffer for three times and different concentration (0, 0.2 and 0.4 mM) of ADA in serum
containing media was added to the cells and further incubated at 37 ºC for 24 h. The cell
viability was then determined by using Alamar blue assay.

TEM sample preparation
TEM samples of nanoparticles were prepared by placing one drop of the desired
nanoparticles solution (1~3 µM) on to a 300-mesh Cu grid coated with carbon film,
followed by 2 % of uranyl acetate staining for 15 min. These samples were analyzed and
photographed using JEOL 100S electron microscopy.
For the preparation of cellular TEM samples, MCF-7 cells were seeded and incubated
on 15 mm diameter Theramanox® coverslips (Nalge Nunc International, NY) placed in
24 well plates at amount of 100,000 cells in 1 ml of serum containing media for 24 h
prior to the experiment. The media was replaced by 0.5 ml of 2 µM AuNP-NH2 or
AuNP-NH2-CB[7] in serum containing media and incubated for 24 h. The medium
containing the gold nanoparticles was then discarded and the cells were completely
washed with PBS buffer for three times. The cells were then fixed in 2 % glutaraldehyde
with 3.75 % sucrose in 0.1 M sodium phosphate buffer (pH 7.0) for 30 min and then
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washed with 0.1 M PBS containing 3.75% sucrose three times over 30 min. They were
postfixed in 1 % osmium tetroxide with 5 % sucrose in 0.05 M sodium phosphate buffer
solution (pH 7.0) for 1 hr and the rinsed with distilled water three times. They were
dehydrated in a graded series of acetone (10 % step), and embedded in epoxy resin. The
resin was polymerized at 70 °C for 12 h. Ultrathin sections (50 nm) obtained with a
Reichert Ultracut E Ultramicrotome and imaged under a JEOL 100S electron
microscopy.
For the preparation of TEM samples for the cells treated with AuNP-NH2-CB[7] and
subsequent incubation with ADA, pre-seeded MCF-7 cell on 15 mm diameter
Theramanox® coverslips was treated by AuNP-NH2-CB[7] (2 M) for 3h. After washing
three times with PBS buffer, the cells were further incubated with ADA (0.4 mM) in
serum containing media for 24 h. Cellular TEM sample was prepared according to the
above described procedure.

ICP-MS sample preparation and experimental setup
ICP-MS measurements were performed on a Perkin Elmer Elan 6100. Operating
conditions of the ICP-MS are listed below: RF power: 1200 W; plasma Ar flow rate: 15
L/min; nebulizer Ar flow rate: 0.96 L/min; isotopes monitored: 197Au; dwell time: 50 ms;
nebulizer: cross flow; spray chamber: Scott. AuNP-NH2 and AuNP-NH2-CB[7] (0.5 M)
was incubated with pre seeded MCF-7 cell line in 24 well plates (20,000 cells/well) for
3h. After incubation, cells were washed three times with PBS buffer and then lysis buffer
(250 l) was added to the cells. The resulting cell lysate was digested overnight using 3
mL of HNO3 and 1 mL of H2O2. On the next day, 3 mL of aqua regia was added, and
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then the sample was allowed to react for another 2-3 h. The sample solution was then
diluted to 100 mL with de-ionized water, and aqua regia. The final gold nanoparticle
sample solution contained 5% aqua regia. The gold nanoparticle sample solution was
measured by ICP-MS under the operating conditions described above. Cellular uptake
experiments with each gold nanoparticle were repeated 3 times, and each replicate was
measured 5 times by ICP-MS. A series of gold standard solutions (20, 10, 5, 2, 1, 0.5,
0.2, 0 ppb) were prepared before each experiment. Each gold standard solution contained
5% aqua regia. The resulting calibration line was used to determine the gold amount in
taken up by the cells in each sample.

Matrix Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS)
The MALDI analyses were done on a Bruker Omniflex time-of-flight mass
spectrometer. The spectrometers are equipped with a 337 nm nitrogen laser, a 1.0 m
flight tube, and a stainless steel sample target. All mass spectra were acquired in a
reflectron mode, using a reflectron voltage of 20 kV. All reported spectra represent an
average of 100 shots. A saturated matrix (α-cyano-4-hydroxycinnamic acid (α-CHCA))
solution was prepared in 70% acetonitrile, 30% H2O, and 0.1% trifluoroacetic acid. 1 μL
of matrix solution was mixed with 1 μL of nanoparticle solution. 1 μL of this mixture was
applied to target, and after allowing it to dry, the MALDI-MS analysis was performed.

Thermogravimetric analysis (TGA)
TGA was performed using a TGA 2950 high-resolution thermo-gravimetric analyzer
(TA Instruments, Inc., New Castle, DE), which was equipped with an open platinum pan
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and an automatically programmed temperature controller. The TGA data were obtained
as follows: about 3.0 mg of AuNP-NH2 was placed in the TGA pan and heated in a
nitrogen atmosphere at a rate of 5 °C / min up to 500 °C. The mass change was plotted
against temperature to generate the thermogravimetric combustion profile of AuNP-NH2.
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CHAPTER 5

REGULATING EXOCYTOSIS OF GOLD NANOPARTICLES VIA HOSTGUEST CHEMISTRY

5.1 Introduction
Drug delivery systems (DDSs) improve the efficacy of conventional
pharmaceutics through enhanced pharmacokinetics and biodistribution. 1 Drugs can be
both covalently and non-covalently incorporated into DDSs. 2 Successful therapy with
DDSs achieves accurate delivery of their associated drugs to target cells through
controlled drug release.3 Release of drugs from carriers can be regulated by employing
tunable activation strategies (e.g. hydrolysis or degradation) via relevant stimuli (e.g. the
low endosomal pH, light, and cytosolic reductive conditions). 4 , 5 , 6 Because greater
antiproliferative activity of the drugs relies on the sustained therapeutic effect inside
cells, cellular uptake and subsequent long-term retention of the drug carriers within the
cells are required for efficient DDSs.7, 8, 9
One of the main obstacles of DDSs, however, is the rapid removal of the
internalized drug carriers by exocytosis from the cells before the loaded therapeutics are
effective.10, 11 Exocytosis is the process of expelling wastes and other large molecules out
of the cells,12 which is also commonly observed with a wide variety of drug carriers.13, 14
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As an example, internalized poly (D,L-lactide-co-glycolide) nanoparticles undergo
exocytosis to the extent of 65 % at 30 min and 85 % at 6 h.15 Reducing exocytosis of the
nanoparticulate drug carriers thus can lead their prolonged retention and sustained release
of the loaded drugs inside of the cells, enhancing therapeutic efficiency of the DDSs.16, 17
To date, there have been no reported strategies preventing exocytosis of the nanoparticles.
Furthermore, developing strategies for an orthogonal control of the exocytosis in the
cellular environment is a major challenge because of the intracellular chemical
complexity and a potential toxicity of relevant reagents. To solve the issues, an
orthogonally non-toxic modular system under biological condition should be addressed.
Supramolecular chemistry can develop controlled assemblies from molecular
building blocks by virtue of reversible non-covalent interactions including hydrogen
bonding and van der Waals interactions.18 Due to their modular properties toward other
complementary molecules, host-guest supramolecular complexes can be tuned to
assemble and dissemble in response to various triggers,19 providing a powerful tool for
creating a number of host-guest systems for therapeutic applications.20, 21, 22 Of the hostguest systems, the use of cucurbit[n]ril (CB[n]) family is useful due to its ability to form
stable host-guest complexes with a wide variety of guest molecules in aqueous media,23,
24

and its non-toxic behavior in vitro and in vivo. 25,

26

Various CB[n]-guest systems have

been developed to create delivery vectors for the drugs and other therapeutic materials,
and an actuator system to control catalytic activity of an enzyme. 27 ,

28 , 29

Moreover,

owing to the high binding affinity of CB[n] to guest molecules (up to 1013 M-1),
engineering of the host-guest systems provides the capability of actuation for the
regulation of therapeutics in living cells.30, 31
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In this work, we describe a strategy to regulate exocytosis of AuNPs by utilizing
the host-guest system on gold nanoparticles (AuNPs).32, 33 Quaternary amine head group
terminated cationic gold nanoparticles (AuNP-TBen) were readily taken up by the cells
via endocytosis (Figure 5.1). Afterward, in situ treatment of a complementary
cucurbit[7]uril (CB[7]) resulted in threading of the CB[7] on AuNP-TBen inside the cells.
The AuNP-TBen-CB[7] complexation rendered the surface of the particles less
hydrophilic, inducing the assemblies of AuNP-TBen-CB[7] sequestered in the endosome.
Exocytosis of the AuNP-TBen-CB[7] was then blocked by the increased size of the
induced assemblies. This approach provide a new strategy for improving efficacy of drug
delivery systems through prolonged retention of drug carriers within the cells.
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Figure 5.1 Controlling exocytosis of the nanoparticle by using intracellular host-guest
complexation. (a) Inhibition of AuNP-TBen exocytosis by threading of CB[7] on the
nanoparticle surface. (b) Inducement of the AuNP-TBen-CB[7] assemblies.

5.2 Results and discussion
5.2.1 Complexation between AuNP-TBen and CB[7]
Exocytosis of nanoparticles is dependent on their size.7 Larger nanoparticles
(more than 100 nm in diameter) undergo exocytosis at slower rate and lower amount than
smaller nanoparticles. Therefore, the underlying principle of controlling exocytosis of
nanoparticles is to induce in situ growth of assemblies from the internalized individual
nanoparticles entrapped in endocytic vesicles by using a host-guest supramolecular
system. The exocytosis of the particles then would be blocked by the increased size of the
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induced assemblies 34 and the host-guest system provides an orthogonal stimulus,
allowing temporal control of the exocytosis (Figure 5.1 (b)).
To provide an effective host-guest supramolecular system, we synthesized a
water-soluble gold nanoparticle, AuNP-TBen, featuring a tetra(ethylene glycol) and
quaternary benzyl amine head group at terminal ligand via a Murray’s place-exchange
reaction.35 The detailed syntheses and characterization of the AuNPs are available in the
Supporting Information. The gold core had an average size of 2.1 ± 0.5 nm with
hydrodynamic diameter of the AuNP-TBen being 9.7 ± 0.1 nm determined by TEM and
dynamic light scattering, respectively. The AuNP-TBen had a positive potential of + 14.2
mV. The terminal quaternary benzyl amine moiety serves as a recognition unit for the
formation of a host-guest inclusion complex with CB[7] with the association constant of
~ 10-8 M-1.36 This higher binding constant is strong enough for the complexes to remain
stable under biological conditions.37

5.2.2 Inducing assemblies of AuNP-TBen-CB[7]
The complexation between AuNP-TBen and CB[7] was investigated by using
DLS experiments as shown in Figure 5.2(a). At the molar ratio of 1:1 and 1:2 (AuNPTBen:CB[7]), the hydrodynamic diameter of the AuNP-TBen slightly increased from 9.7
± 0.1 to 11.6 ± 0.5 nm. At a ratio of 1:4 (AuNP-TBen:CB[7]), the particles began to
assemble to each other and were completely assembled (aggregated) precipitating at the
ratio of 1:10 (AuNP-TBen:CB[7]) as shown in Figure 5.1 (b). The controls, AuNPTTMA and AuNP-TCOOH showed no observable change of diameter upon adding CB[7]
as both particles have no interaction with CB[7].
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Figure 5.2 Inducing assemblies of the nanoparticle upon binding with CB[7] and effect
of surface functional group of the particle. (a) DLS experiments of the nanoparticles
depending on addition of CB[7]. It is noted that AuNP-TBens were completely
assembled (aggregated) and precipitated at the ratio of 1:10 (AuNP-TBen:CB[7]). (b)
AuNP-ADA and AuNP-TMC6 induce the assemblies upon binding with CB[7] (at the
ratio of 1:10 (AuNPs:CB[7]), but not for AuNP-TMOH and AuNP-TMNH2 with polar
end groups. Inducement of the assemblies of the particles is dependent on surface
functional group of the particles

To explain the rationale of the induced assemblies of the AuNP-TBen-CB[7],
inducement of the assemblies upon binding with CB[7] was carried out with
nanoparticles having different surface functional groups (Figure 5.2 (b)). AuNP-ADA
and AuNP-TMC6 induced the assemblies (aggregates) upon binding with CB[7] (at the
ratio of 1:10 (AuNPs:CB[7]) as AuNP-TBen-CB[7] complex. In contrast, AuNP-TMOH
and AuNP-TMNH2 could not induce assemblies although the particles-CB[7] complexes
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were formed. This indicates that the surface end group of the particles plays important
role in inducing the assemblies of the particles.
The amphiphilic nanoparticle, AuNP-TBen (also AuNP-ADA and AuNP-TMC6)
are soluble in both aqueous and organic solvent (e.g. dichloromethane), respectively. In
the aqueous solution, the hydrophobic benzyl units on the particles are probably hidden
from the external environment, making the surface of the particles hydrophilic and
soluble in aqueous media. Upon binding with CB[7], the benzyl units on the particle
presumably became stretched out along the particle, rendering the surface of the particle
forcefully less hydrophilic, decreasing their solubility, and inducing the assemblies
(Figure 5.1 (b)). AuNP-TMOH and AuNP-TMNH2 can bind with CB[7] but hydroxyl
and amine end group potentially kept the surface of particles hydrophilic, and therefore
not allowing assemble of the particles. It indicates that inducing assemblies is dependent
on surface functional group of the particles.
When the particle assemblies of AuNP-TBen-CB[7] were treated with excess of
1-adamantyl amine (ADA), CB[7] is dethreaded from the particle through creation of the
more favorable 1:1 ADA-CB[7] complexes (Ka = 1.7 x 1012).24 Addition of ADA
triggered the particle assemblies to disassemble, making the particles soluble back into
the PBS (Figure 5.3). This indicates that exploiting host-guest systems on AuNPs can
control solubility (hydrophobicity) of the AuNPs by using precise ‘lock and key’
modulation over their molecular-level interactions.
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Figure 5.3 (a) AuNP-TBen in PBS. (b) AuNP-TBen-CB[7] assemblies (c) When the
particle assemblies of AuNP-TBen-CB[7] were treated with excess of 1-adamantyl amine
(ADA), ADA triggered the particle assemblies to disassemble, making the particles
soluble back in PBS.

5.2.3 Controlling exoctosis of AuNP-TBen-CB[7]
Cellular uptake behaviors of the nanoparticles were investigated by TEM analysis
of the cell. After 3h incubation of the cationic AuNP-TBen (200 nM), the particles were
shown to be trapped in the endosomal vesicles in cytoplasm as shown in Figure 5.4 (a).
This observation is consistent with a endocytotic behavior of other cationic nanoparticles
previously reported in literatures. 38 ,

39

To study the exocytotic behaviors of the

nanoparticle, after 3h incubation of the AuNP-TBen (200 nM), the cells were washed off
and incubated with fresh media or CB[7] (0.2 mM) media for an additional 24h. When
the cells were treated by fresh media, the number of the particle-entrapped vesicles was
significantly decreased (Figure 5.4 (b)). Only a few particles remained within the vesicles
or dispersed in various organelles, indicating a major portion of the removed AuNP-TBen
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from the cells were involved in exocytosis. In contrast, when the cells were treated by the
CB[7] media (0.2 mM) to induce assemblies of AuNP-TBen-CB[7], the particles
remained trapped in the endosome (Figure 5.4 (c)). These results indicate that treatment
of CB[7] caused intracellular assemblies of the AuNP-TBen-CB[7] as the CB[7] can
cross the cell membrane 40 and the induced bulky assemblies remained sequestered in
endocytic vesicles without exocytosis.

Figure 5.4 Cellular uptake and intracellular behavior of the gold nanoparticles. (a) TEM
images of cross sectional MCF-7 cells incubated for 3 h with 200 nM of AuNP-TBen.
The cationic AuNP-TBen seems to be trapped in organelles such as an endosome (in the
red circle). (b) TEM images of cross sectional MCF-7 cells incubated for 3 h with 200
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nM of AuNP-TBen and then washed off and further incubation with only cell culture
media for 24 h. The number of the particle-entrapped endosomal vesicles was
significantly decreased. (c) TEM images of cross sectional MCF-7 cells incubated for 3 h
with 200 nM of AuNP-TBen and then washed off and further incubation with cell culture
media of CB[7] (0.2 mM) for 24 h. (d) Quantification of the amount of gold retained in
cells at different time (0 h, 3 h, 12 h, and 24 h). Samples at each time point were analyzed
by ICP-MS to determine the amount of gold in MCF-7 cell after 3 h incubation with 200
nM of AuNP-TBen and washed off and further incubation with media or media of CB[7]
(0.2 mM). Cellular uptake experiments with each gold nanoparticle were repeated 3
times, and each replicate was measured 5 times by ICP-MS. Error bars represent the
standard deviations of these measurements.

The excocytosis of the nanoparticles was further quantified by using inductively
coupled plasma mass spectrometry (ICP-MS). After 3h incubation of AuNP-TBen (200
nM), the cells were completely washed off and replaced by fresh cell culture media or
CB[7] (0.2 mM) media. The cells were then incubated for different additional times (0 h,
3 h, 12 h, and 24 h) and the amount of the gold nanoparticle retained by the cells was
determined by measuring ICP-MS. Retention of the AuNP-TBen treated by only cell
culture media decreased 34 % at 24 hours while no significant change was observed for
the media of CB[7] treatment (Figure 5.4 (d)). This result revealed that treatment of the
CB[7] on the cells inhibited exocytosis of the AuNP-TBen along with the observed TEM
results.
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5.2.4 Effect of an end group on the exocytosis
To further investigate the effect of an end group of AuNPs on the exocytosis,
retention of the particles with different functional head groups in the cells was measured
by using ICP-MS. AuNP-TTMA and AuNP-TMOH (Figure 5.4 (a) and (b)) exhibited no
significant difference of exocytotic behavior for both media and media of CB[7]
treatments, showing no effect of CB[7] on exocytosis of the AuNPs. Retention of the
AuNP-TTMA and AuNP-TMOH decreased to ~ 62 % and ~ 70 % at 24h, respectively,
regardless of CB[7] treatment. In the other hand, exocytosis of the AuNP-ADA and
AuNP-TMC6 was blocked when the cells were treated by media of CB[7] as the AuNPTBen (Figure 5.5 (c) and (d)). Amount of the retained AuNP-ADA and AuNP-TMC6 in
the cells reduced to ~ 75 % and ~ 70 % at 24h for the media treatment. Both AuNP-ADA
and AuNP-TMC6 induced assemblies of the particle upon binding with CB[7] as AuNPTBen. It indicates that CB[7] itself does not affect cellular uptake of the particles and
exocytosis of the particles was caused increased size of the assemblies.
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Figure 5.5 Effect of a surface functional group on exocytotic behavior of AuNPs. ICMMS measurements of (a) AuNP-TTMA, (b) AuNP-TMOH, (c) AuNP-TMC6, and (d)
AuNP-ADA. Quantification of exocytosis of the particles were determined by analyzing
ICP-MS on MCF-7 cell with same experimental condition carried out on the AuNP-TBen.
AuNP-TTMA does not bind with CB[7]. AuNP-TMOH binds with CB[7] but does not
induce assemblies. Both AuNP-ADA and AuNP-TMC6 induced assemblies of the
particle upon binding with CB[7]. Cellular uptake experiments with each gold
nanoparticle were repeated 3 times, and each replicate was measured 5 times by ICP-MS.
Error bars represent the standard deviations of these measurements.

5.2.5 Cellular viability
Cellular proliferative activity was measured by alamar blue assay to evaluate
possible toxicity that might arise from nanoparticles while retained in the cells. As shown
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in Figure 5.6, all the nanoparticles exhibited no decrease in cell viability for the treatment
of both media and media of CB[7] (0.2 mM). It shows that the induced assemblies of the
particles sequestered in endocytic vesicles do not affect cell viability.

Figure 5.6 Cytotxicity of gold nanoparticles. After 3h incubation of AuNPs (200 nM) in
MCF-7 cell, the cells were washed off and further incubated with media and media of
CB[7] (0.2 mM) at 37 ºC for 24 h. The cell viability was then determined by using
Alamar blue assay. As a control, CB[7], cell viability of CB[7] (0.2 mM) was measured
after 24 h incubation.

5.3 Summary and future outlook
In conclusion, we have demonstrated a methodology for regulating exocytosis of
the internalized nanoparticles. Utilizing supramolecular host-guest system on the AuNPs
induced the assemblies of the particles in the living cells, preventing their exocytosis
without any observed cytotoxicity. This approach would provide a potential strategy for
prolonged retention of drug carriers within endosome, enabling sustained therapeutic
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effect of the carriers. We are currently exploring this strategy with AuNPs featuring
prodrugs tethered with labile linkage which can be degraded by external stimuli.
Additionally, this approach also will be applied to other nanomaterials with potential
utility of their prolonged transplantation in a wide variety of cells for in vivo cellular
tracking41 and tumor-targeted delivery of therapeutic systems.42

5.4 Synthesis of materials and experimental methods
General
All the chemicals were purchased from Sigma-Aldrich or Fischer Scientific, unless
otherwise specified. The chemicals were used as received. Gold nanoaprticles used in this
work have been reported previously. 43 1H NMR spectra were recorded at 400 MHz on a
Bruker AVANCE 400 machine. Hewlett-Packard 8452A UV-Vis spectrophotometer was
used to record UV-Vis spectra. Dynamic light scattering (DLS) was measured by
Zetasizer Nano ZS. The fluorescence from the Alamar blue assay was measured in a
SpectraMax M5 microplate spectrophotometer.

ICP-MS sample preparation and measurements
ICP-MS measurements were performed on a Perkin Elmer Elan 6100. Operating
conditions of the ICP-MS are listed below: RF power: 1200 W; plasma Ar flow rate: 15
L/min; nebulizer Ar flow rate: 0.96 L/min; isotopes monitored: 197Au; dwell time: 50 ms;
nebulizer: cross flow; spray chamber: Scott. Gold nanoparticles (200 nM, 0.5 ml) was
incubated with pre-seeded MCF-7 cell line in 24 well plates (20,000 cells/well) for 3h.
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After incubation, cells were washed three times with PBS buffer and then 0.5 mL of
media or media of CB[7] (0.2 mM) was added to the cells. The wells of the plates then
connected to a peristaltic pump which provides a continuous flow of the media and media
of CB[7] to remove exocytosed nanoparticles. The cells were then incubated for different
additional times (0 h, 3 h, 12 h, and 24 h). Cells were washed three times with PBS buffer
and then lysis buffer (300 l) was added to the cells. The resulting cell lysate was
digested overnight using 3 mL of HNO3 and 1 mL of H2O2. On the next day, 3 mL of
aqua regia was added, and then the sample was allowed to react for another 2-3 h. The
sample solution was then diluted to 100 mL with de-ionized water, and aqua regia. The
final gold nanoparticle sample solution contained 5% aqua regia. The gold nanoparticle
sample solution was measured by ICP-MS under the operating conditions described
above. Cellular uptake experiments with each gold nanoparticle were repeated 3 times,
and each replicate was measured 5 times by ICP-MS. A series of gold standard solutions
(20, 10, 5, 2, 1, 0.5, 0.2, 0 ppb) were prepared before each experiment. Each gold
standard solution contained 5% aqua regia. The resulting calibration line was used to
determine the gold amount in taken up by the cells in each sample.

Cellular TEM measurements
For a preparation of cellular TEM samples, MCF-7 cells were seeded and incubated on
15 mm diameter Theramanox® coverslips (Nalge Nunc International, NY) placed in 24
well plates at amount of 100,000 cells in 1 ml of serum containing media for 24 h prior to
the experiment. The media was replaced by 0.5 ml of 200 nM AuNP-TBen in serum
containing media and incubated for 3 h. The cells were completely washed with PBS
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buffer for three times and then 0.5 mL of media or media of CB[7] (0.2 mM) was added
to the cells. After another 24 h incubation, the cells were then fixed in 2 % glutaraldehyde
with 3.75 % sucrose in 0.1 M sodium phosphate buffer (pH 7.0) for 30 min and then
washed with 0.1 M PBS containing 3.75% sucrose three times over 30 min. They were
postfixed in 1 % osmium tetroxide with 5 % sucrose in 0.05 M sodium phosphate buffer
solution (pH 7.0) for 1 hr and the rinsed with distilled water three times. They were
dehydrated in a graded series of acetone (10 % step), and embedded in epoxy resin. The
resin was polymerized at 70 °C for 12 h. Ultrathin sections (50 nm) obtained with a
Reichert Ultracut E Ultramicrotome and imaged under a JEOL 100S electron
microscopy.

Cell culture and cytoxicity TEM measurements
MCF-7 cells were grown in a cell culture flask using low glucose Dulbecco's Modified
Eagle Medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified
atmosphere of 5% CO2. For a cytotoxicity test, MCF-7 cells were seeded at 20,000 cells
in 0.2 ml per well in 96-well plates 24 h prior to the experiment. During experiment old
media was replaced by 0.2 ml of nanoparticles (200 nM) in serum containing media and
the cells were incubated for 3 h at 37°C in a humidified atmosphere of 5 % CO2. The
cells were then completely washed with PBS buffer for three times and media or media
of CB[7] (0.2 mM) was added to the cell. After another 24h incubation, the cells were
then completely washed off and 10% Alarmar blue in serum containing media was added
to each well and further incubated at 37 °C for 4 h. The cell viability was then determined
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by measuring the fluorescence intensity at 570 nm using a SpectraMax M5 microplate
spectrophotometer.

5.5 References

1. Allen, T. M.; Cullis, P. R., Drug delivery systems: Entering the mainstream. Science
2004, 303 (5665), 1818-1822.
2. Torchilin, V. P., Structure and design of polymeric surfactant-based drug delivery
systems. J. Control. Release. 2001, 73 (2-3), 137-172.
3 . Peer, D.; Karp, J. M.; Hong, S.; FaroKHzad, O. C.; Margalit, R.; Langer, R.,
Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2
(12), 751-760.
4. Duncan, R., The dawning era of polymer therapeutics. Nat. Rev. Drug. Discov. 2003, 2
(5), 347-360.
5. Agasti, S. S.; Chompoosor, A.; You, C. C.; Ghosh, P.; Kim, C. K.; Rotello, V. M.,
Photoregulated Release of Caged Anticancer Drugs from Gold Nanoparticles. J. Am.
Chem. Soc. 2009, 131 (16), 5728-5729.
6. Hong, R.; Han, G.; Fernandez, J. M.; Kim, B. J.; Forbes, N. S.; Rotello, V. M.,
Glutathione-mediated delivery and release using monolayer protected nanoparticle
carriers. J. Am. Chem. Soc. 2006, 128 (4), 1078-1079
7. Chithrani, B. D.; Chan, W. C. W., Elucidating the mechanism of cellular uptake and
removal of protein-coated gold nanoparticles of different sizes and shapes. Nano. Lett.
2007, 7 (6), 1542-1550.

151

8 . Klostranec, J. M.; Chan, W. C. W., Quantum dots in biological and biomedical
research: Recent progress and present challenges. Adv. Mater. 2006, 18 (15), 19531964.
9. Hong, R.; Han, G.; Fernandez, J. M.; Kim, B. J.; Forbes, N. S.; Rotello, V. M.,
Glutathione-mediated delivery and release using monolayer protected nanoparticle
carriers. J. Am. Chem. Soc. 2006, 128 (4), 1078-1079
10. Panyam, J.; Zhou, W. Z.; Prabha, S.; Sahoo, S. K.; Labhasetwar, V., Rapid endolysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for
drug and gene delivery. Faseb. J. 2002, 16 (10).
11 . Panyam, J.; Labhasetwar, V., Sustained cytoplasmic delivery of drugs with
intracellular receptors using biodegradable nanoparticles. Mol. Pharmaceut. 2004, 1
(1), 77-84.
12. Pickett, J. A.; Edwardson, J. M., Compound exocytosis: Mechanisms and functional
significance. Traffic 2006, 7 (2), 109-116.
13. Slowing, I. I.; Vivero-Escoto, J. L.; Zhao, Y.; Kandel, K.; Peeraphatdit, C.; Trewyn,
B. G.; Lin, V. S. Y., Exocytosis of Mesoporous Silica Nanoparticles from
Mammalian Cells: From Asymmetric Cell-to-Cell Transfer to Protein Harvesting.
Small 2011, 7 (11), 1526-1532.
14. Chavanpatil, M. D.; Handa, H.; Mao, G.; Panyam, J., Incorporation of phospholipids
enhances cellular uptake and retention of surfactant-polymer nanoparticles. J. Biomed.
Nanotechnol. 2007, 3 (3), 291-296.

152

15. Panyam, J.; Labhasetwar, V., Dynamics of endocytosis and exocytosis of poly(D,Llactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharmaceut. Res.
2003, 20 (2), 212-220.
16. Sahoo, S. K.; Labhasetwar, V., Enhanced anti proliferative activity of transferrinconjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular
drug retention. Mol. Pharmaceut 2005, 2 (5), 373-383.
17 . Vasir, J. K.; Labhasetwar, V., Quantification of the force of nanoparticle-cell
membrane interactions and its influence on intracellular trafficking of nanoparticles.
Biomaterials 2008, 29 (31), 4244-4252.
18. Lehn, J. M. Supramolecular Chemistry: Concepts and Perspectives. (VCH, New
York, 1995).
19. Klajn, R.; Olson, M. A.; Wesson, P. J.; Fang, L.; Coskun, A.; Trabolsi, A.; Soh, S.;
Stoddart, J. F.; Grzybowski, B. A., Dynamic hook-and-eye nanoparticle sponges. Nat.
Chem. 2009, 1 (9), 733-738.
20. Angelos, S.; Yang, Y. W.; Patel, K.; Stoddart, J. F.; Zink, J. I., pH-responsive
supramolecular nanovalves based on cucurbit[6]uril pseudorotaxanes. Angew. Chem.
Int. Edit. 2008, 47 (12), 2222-2226.
21. Angelos, S.; Khashab, N. M.; Yang, Y. W.; Trabolsi, A.; Khatib, H. A.; Stoddart, J.
F.; Zink, J. I., pH Clock-Operated Mechanized Nanoparticles. J. Am. Chem. Soc.
2009, 131 (36), 12912.

153

22. Coti, K. K.; Belowich, M. E.; Liong, M.; Ambrogio, M. W.; Lau, Y. A.; Khatib, H.
A.; Zink, J. I.; Khashab, N. M.; Stoddart, J. F., Mechanised nanoparticles for drug
delivery. Nanoscale 2009, 1 (1), 16-39.
23. Kim, K.; Selvapalam, N.; Ko, Y. H.; Park, K. M.; Kim, D.; Kim, J., Functionalized
cucurbiturils and their applications. Chem. Soc. Rev. 2007, 36 (2), 267-279.
24. Lagona, J.; Mukhopadhyay, P.; Chakrabarti, S.; Isaacs, L., The cucurbit[n]uril family.
Angew. Chem. Int. Edit. 2005, 44 (31), 4844-4870.
25. Hettiarachchi, G.; Nguyen, D.; Wu, J.; Lucas, D.; Ma, D.; Isaacs, L.; Briken, V.,
Toxicology and Drug Delivery by Cucurbit[n]uril Type Molecular Containers. Plos
One 2010, 5 (5).
26. Uzunova, V. D.; Cullinane, C.; Brix, K.; Nau, W. M.; Day, A. I., Toxicity of
cucurbit[7]uril and cucurbit[8]uril: an exploratory in vitro and in vivo study. Org.
Biomol. Chem. 2010, 8 (9), 2037-2042.
27. Lim, Y. B.; Kim, T.; Lee, J. W.; Kim, S. M.; Kim, H. J.; Kim, K.; Park, J. S., Selfassembled ternary complex of cationic dendrimer, cucurbituril, and DNA:
Noncovalent strategy in developing a gene delivery carrier. Bioconjugate Chem. 2002,
13 (6), 1181-1185.
28. Kim, S. K.; Park, K. M.; Singha, K.; Kim, J.; Ahn, Y.; Kim, K.; Kim, W. J.,
Galactosylated cucurbituril-inclusion polyplex for hepatocyte-targeted gene delivery.
Chem. Commun. 2010, 46 (5), 692-694.
29. Ghosh, S.; Isaacs, L., Biological Catalysis Regulated by Cucurbit[7]uril Molecular
Containers. J. Am. Chem. Soc. 2010, 132 (12), 4445-4454.

154

30. Kim, C.; Agasti, S. S.; Zhu, Z. J.; Isaacs, L.; Rotello, V. M., Recognition-mediated
activation of therapeutic gold nanoparticles inside living cells. Nat. Chem. 2010, 2
(11), 962-966.
31. Kim, J.; Ahn, Y.; Park, K. M.; Kim, Y.; Ko, Y. H.; Oh, D. H.; Kim, K., Carbohydrate
wheels: Cucurbituril-based carbohydrate clusters. Angew. Chem. Int. Edit. 2007, 46
(39), 7393-7395.
32 . Kim, C. K.; Ghosh, P.; Rotello, V. M., Multimodal drug delivery using gold
nanoparticles. Nanoscale 2009, 1 (1), 61-67.
33. Ghosh, P.; Han, G.; De, M.; Kim, C. K.; Rotello, V. M., Gold nanoparticles in
delivery applications. Adv. Drug Deliver. Rev. 2008, 60 (11), 1307-1315.
34. Nam, J.; Won, N.; Jin, H.; Chung, H.; Kim, S., pH-Induced Aggregation of Gold
Nanoparticles for Photothermal Cancer Therapy. J. Am. Chem. Soc. 2009, 131 (38),
13639-13645.
35. Templeton, A. C.; Wuelfing, M. P.; Murray, R. W., Monolayer protected cluster
molecules. Acc. Chem. Res. 2000, 33 (1), 27-36.
36. Yuan, L. N.; Wang, R. B.; Macartney, D. H., Chiroptic behaviour of a chiral guest in
an achiral cucurbit[7]uril host. Tetrahedron: Asymmetry 2007, 18 (4), 483-487.
37 . Wheate, N. J., Improving platinum(II)-based anticancer drug delivery using
cucurbit[n]urils. J. Inorg. Biochem. 2008, 102 (12), 2060-2066.
38. Zhu, Z. J.; Ghosh, P. S.; Miranda, O. R.; Vachet, R. W.; Rotello, V. M., Multiplexed
Screening

of

Cellular

Uptake

of

155

Gold

Nanoparticles

Using

Laser

Desorption/Ionization Mass Spectrometry. J. Am. Chem. Soc. 2008, 130 (43), 1413914143.
39. Kim, C. K.; Ghosh, P.; Pagliuca, C.; Zhu, Z. J.; Menichetti, S.; Rotello, V. M.,
Entrapment of Hydrophobic Drugs in Nanoparticle Monolayers with Efficient
Release into Cancer Cells. J. Am. Chem. Soc. 2009, 131 (4), 1360-1361.
40. Montes-Navajas, P.; Gonzalez-Bejar, M.; Scaiano, J. C.; Garcia, H., Cucurbituril
complexes cross the cell membrane. Photoch. Photobio. Sci. 2009, 8 (12), 1743-1747.
41. Bulte, J. W. M.; Kraitchman, D. L., Iron oxide MR contrast agents for molecular and
cellular imaging. Nmr. Biomed. 2004, 17 (7), 484-499.
42. Roger, M.; Clavreul, A.; Venier-Julienne, M. C.; Passirani, C.; Montero-Menei, C.;
Menei, P., The potential of combinations of drug-loaded nanoparticle systems and
adult stem cells for glioma therapy. Biomaterials 2011, 32 (8), 2106-2116.
43. Moyano, D. F.; Rotello, V. M., Nano Meets Biology: Structure and Function at the
Nanoparticle Interface. Langmuir 2011, 27 (17), 10376-10385.

156

